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Cannabinoids have been shown to modulate the immune system in vitro and in 
animal models.  A major area of interest is how cannabinoids impact the brain.  A whole 
variety of neuropathies or brain disorders, such as AIDS dementia, Parkinsons disease, 
Multiple Sclerosis and Alzheimers disease, are associated with a hyperinflammatory 
response within the brain.  Microglia, the resident macrophages of the brain, are the 
major cell type responsible for the persistent elicitation of pro-inflammatory cytokines 
(IL-1α, IL-1β, IL-6, TNFα) and other mediators.  In vitro experiments have 
demonstrated that the partial exogenous cannabinoid agonist delta-9-
tetrahydrocannabinol (∆9-THC) and the potent synthetic exogenous cannabinoid agonist 
CP55940 down-regulate the robust production of pro-inflammatory cytokines elicited in
 xv
response to bacterial lipopolysaccharide (LPS) at the mRNA level. These observations 
suggest that cannabinoids, devoid of psychotropic properties, have the potential to 
betherapeutic agents.  These highly lipophilic compounds can pass through the blood 
brain barrier and act through specific cannabinoid receptors, cannabinoid receptor 1 
(CB1) and cannabinoid receptor 2 (CB2).  CB1 and CB2 are expressed in the brain and the 
periphery, respectively, and may serve as molecular targets for ablating chronic brain 
inflammation.  Electrophoretic mobility shift assays (EMSA) were used to assess the 
effects of ∆9-THC and CP55940 on the LPS-induced binding interactions of the universal 
transcription factor NFκB to its cognate promoter binding site in BV-2 microglial-like 
cells. EMSA analyses demonstrated that the ∆9-THC and CP55940 down-regulated LPS-
induced NFκB binding in BV-2 cells in a biphasic manner. Furthermore, reporter activity 
assays determined that ∆9-THC and CP55940 attenuated LPS-induced, NFκB 
transcriptional activity in the same biphasic manner.  We then determined the specificity 
in which cannabinoids inhibit NFκB function.  Real-Time RT-PCR analysis 
demonstrated that BV-2 cells did not express CB1 mRNA, but they do express CB2 
mRNA when untreated and stimulated with IFN-γ or LPS.  We performed specificity 
studies using CB1 and CB2 selective agonists and antagonists with our reporter activity 
assays.  The CB1-selective agonist ACEA did not affect NFκB transcriptional activity but 
the CB2-selective agonist O-2137 exerted a significant decrease in activity.  Furthermore, 
the CB1 antagonist SR141716A could not reverse the inhibitory effects of CP55490 but 
those effects were blocked by the CB2 antagonist SR144528.  Lastly, we determined the 
site of action in which cannabinoids inhibit NFκB function by assessing the effects of ∆9-
 xvi
THC and CP55940 on NFκBs inhibitor protein IκBα.  IκBα retains NFκB in the 
cytoplasm until stimulus-induced cell activation.  Neither cannabinoid compound was 
able to inhibit the phosphorylation of IκBα, which initiates its degradation.  However 
both cannabinoids inhibited the complete degradation of IκBα.  Western immunoblot 
analysis also demonstrated that comparable levels of endogenous and phosphorylated 
p65, the transactivation subunit of the NFκB protein (p65/p50), were detected in the 
nucleus of LPS-stimulated BV-2 cells pre-treated with or without ∆9-THC.  These results 
suggest that, in addition to inhibiting the proteolytic degradation of IκBα, there is also a 
mechanism of action in the nucleus that prevents the proper binding and subsequent 
transcriptional activity of NFκB.  Collectively, these results suggest that cannabinoids 
suppress pro-inflammatory cytokine gene expression at the transcriptional level, but it is 
likely that there is more than one signal transduction pathway involved in the 
cannabinoid-mediated inhibition of NFκB function. 
 
 
 
 
 
 
 
 
 
 1
Introduction 
 
 
 
Cannabinoids 
The marijuana plant Cannabis sativa has a multitude of constituents including the 
highly lipophilic, terpenoid-like compounds identified as cannabinoids, of which over 60 
of these have been identified.  Exogenous cannabinoids describe those compounds that 
have been isolated directly from the marijuana plant, such as delta-9-
tetrahydrocannibanol (∆9-THC), cannabinol (CBN) and cannabidiol (CBD) or those that 
are chemically synthesized in the laboratory, such as the antagonists SR141716A, 
SR144528, and agonists WIN55212-2 and CP55490.  WIN55212-2 and CP55940 are full 
receptor agonists, therefore eliciting maximum responses upon cannabinoid receptor 
interaction.    Endogenous cannabinoids or endocannabinoids exist as part of a native 
endocannabinoid system that includes the endocannabinoids anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), cannabinoid receptors and the mediators responsible for 
endocannabinoid synthesis, transport/uptake and degradation.  Endocannabinoids act as 
neurotransmitters and upon release, activate cannabinoid receptors locally or on nearby 
cells.  But unlike other neurotransmitters that are synthesized in advance and stored in 
vesicles, endocannabinoids are produced on demand.  AEA was the first 
endocannabinoid to be identified and was isolated from porcine brain (Devane et al., 
1992). The isolation of this cannabinoid was followed by the isolation and identification 
of 2-AG from canine gut (Mechoulam et al., 1995). Cannabinoids are the major 
contributors of the euphoric, sedative and cognitive effects experienced by marijuana 
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users, with ∆9-THC being the most psychoactive compound.  Medicinally, cannabinoids 
have been used to stimulate appetite, prevent nausea and diminish pain in patients 
suffering from a multitude of diseases and disorders.  Additionally, cannabinoids 
inherently possess immune modulatory capabilities that may allow these compounds to 
serve as therapeutic agents, specifically in neuropathogenic diseases that are 
pathologically hallmarked by a chronic elicitation of pro-inflammatory mediators by cells 
of the central nervous system (CNS).  ∆9-THC is the major immunomodulatory 
component of marijuana, and has been shown to suppress immune function in a variety of 
immune cells within the periphery (Burnette-Curley and Cabral, 1995; Coffey et al., 
1996; Klein et al., 1991; McCoy et al., 1999; Friedman et al., 1991; Klein and Friedman, 
1990) and within the CNS (Puffenbarger et al., 2000; Facchinetti et al., 2003; Cabral et 
al., 2008; Cabral and Griffin-Thomas, 2008).  ∆9-THC by virtue of its lipophilic nature 
can exert direct effects on immune cells by perturbing cellular membranes (Cabral and 
Staab, 2005; Lawrence and Gill, 1975; Gill and Lawrence, 1976; Makriyannis et al., 
1990) and penetrating the blood brain barrier (BBB) to access cognate cannabinoid 
receptors. 
 
Cannabinoid Receptors 
There are two known cannabinoid receptors, cannabinoid receptor 1 (CB1) and 
cannabinoid receptor 2 (CB2).  CB1 was identified in 1990 from a rat brain cDNA library 
(Matsuda et al., 1990) and is found primarily within the CNS and peripheral tissues such 
as the testis (Galiegue et al., 1995).  CB1 is a 473 amino acid long, seven-transmembrane, 
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G(i/o)-protein coupled inhibitory receptor and is distributed throughout the various 
compartments of the brain, including the cerebellum, cerebral cortex, hippocampus, basal 
ganglia and spinal cord (Matsuda et al., 1990; Herkenham et al., 1990; Westlake et al., 
1994).  Gi-coupled proteins result in a decrease in adenylate cyclase production and 
intracellular calcium (Ca2+) levels (Table 1).  CB1 has since been cloned from rat (Gerard 
et al., 1991) and mouse (Chakrabarti et al., 1995).  Mouse CB1 has been shown to share 
99% and 97% amino acid identity to rat and human CB1, respectively (Chakrabarti et al., 
1995; Klein et al., 1998b).   
The cloning and identification of CB2 soon followed the discovery of CB1.  The 
CB2 was cloned and identified from a human promyelocytic cell line (HL60) cDNA 
library (Munro et al., 1993).  A distinct characteristic of this receptor is that it is 
predominantly distributed in cells and tissues of the peripheral immune system that 
include tonsils, thymus, B and T lymphocytes, monocytes, natural killer (NK) cells, 
polymorphonuclear cells, and macrophages (Galiegue et al., 1995; Schatz et al., 1997).  
After much debate and controversy in recent years, the CB2 also has been identified in the 
CNS.  The majority of CB2 expression within the CNS is attributed to microglial cells 
(Carlisle et al., 2002), the resident macrophages of the brain, particulary during early 
states of inflammation (Nunez et al., 2004; Ramirez et al., 2005a; Cabral and Marciano-
Cabral, 2005; Fernandez-Ruiz et al., 2007).  CB2 is a 360 amino acid long, seven-
transmembrane, G(i/o)-protein coupled inhibitory receptor, and like CB1 is pertussis-toxin 
sensitive with an extracellular, glycosylated N-terminus and an intracellular C-terminus 
(Matsuda et al., 1990; Munro et al., 1993; Howlett et al., 1986).  There is a great level of 
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amino acid identity of CB2 between variant species, for example there is 81% amino acid 
identity between rat and human CB2, and a 93% amino acid identity between rat and 
mouse species (Griffin et al., 2000).   
Reports of the existence of additional cannabinoid receptors continue to amass, 
and are based on investigations utilizing CB1 knockout or CB1/CB2 double-knockout 
mice that demonstrate that pharmacological responses of endogenous, exogenous and 
synthetic cannabinoids are exerted through mechanisms independent of CB1 and CB2 
(Wiley and Martin, 2002; Breivogel et al., 2001; Di Marzo et al., 2000; Jarai et al., 1999).  
Several reports have implied that the GPR55 receptor and the transient receptor potential 
vanilloid 1 (TRPV1) may potentially be novel cannabinoid receptors.  GPR55 is a 
Gsα12/13-protein coupled receptor first cloned and identified from an expressed sequence 
tags (ESTs) database, and like CB1 and CB2 has seven conserved transmembrane 
sequences (Sawzdargo et al., 1999; Baker et al., 2006; Pertwee, 2007).  Gs-coupled 
proteins cause increases in adenylate cyclase production and intracellular Ca2+ levels 
(Table 1).  Exogenous cannabinoids ∆9-THC, CBD, HU-210 and CP55940, and the 
endogenous cannabinoids AEA, 2-AG and noladin ether have been shown to activate 
GPR55 (Ryberg et al., 2007), implicating GPR55 as a novel cannabinoid receptor.  
TRPV1, a ligand-gated cation channel, is a member of the transient receptor potential ion 
channel family and its natural ligands include capsaicin and vanilloids.  The suggestion 
that TRVP1 may be a cannabinoid receptor arises from studies that demonstrated that the 
endogenous cannabinoid AEA, which is structurally similar to capsaicin, can interact 
with and activate this receptor (Smart et al., 2000; Ross, 2003).  Although there is 
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accumulating evidence that additional cannabinoid receptor types exist, a novel 
cannabinoid receptor has yet to be identified that fulfills stringent characterization at both 
the pharmacological and functional levels. 
 
Cannabinoid Receptor Signaling 
CB1 and CB2 take part in signaling cascades involved in the activation and 
regulation of adenylate cyclase, cAMP and mitogen-activated protein (MAP) kinases, and 
intracellular calcium levels.  Upon ligand interaction, the inactive G-protein coupled to 
both cannabinoid receptors is modified to an active state by switching the guanine 
nucleotide GDP to the active GTP.  The heterotrimeric G-protein dissociates into the βγ 
subunit and the α subunit, which binds to adenylate cyclase, inhibits its enzymatic 
activity and prevents synthesis of cyclic AMP (cAMP).  Signaling events that are cAMP-
dependent, such as the activation of cAMP-dependent protein kinase (PKA) and further 
downstream phosphorylation events, are negatively affected by the lack of cAMP.   
These phosphorylation events control ion channel function, and regulation and activation 
of transcription factors.  It is believed that the dimeric βγ subunit is involved in signaling 
pathways distinguishable from those involving the α subunit, such as the MAPK 
signaling cascade (Howlett and Mukhopadhyay, 2000).  The lack of cAMP synthesis due 
to the inactivation of adenylate cyclase describes a mechanism by which CB1 prevents 
neurotransmitter release and, thus maintains homeostasis within the CNS.  Additionally, 
the activation of CB2 and the subsequent linked signaling events represent a mode in 
which CB2-mediated immunological homeostasis is regulated in the brain and periphery.                    
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Microglia 
 Microglia, as resident macrophages in the CNS (Streit et al., 1988; Dickson et al., 
1991; Ling and Wong, 1993), are involved in the remodeling and regeneration of cells 
within this compartment and also provide a first line of defense against infection and 
injury (Blasi et al., 1990; Aloisi, 2001; Facchinetti et al., 2003; Perry, 2004; Cabral and 
Marciano-Cabral, 2005).  These parenchymal cells originate from the same monocyte 
lineage as other tissue macrophages (Facchinetti et al., 2003; Rock et al., 2004; Vilhardt, 
2005 ), and perform some of the same functions including phagocytosis, antigen 
processing and presentation, and production of immune mediators (Giulian and Baker, 
1986; Benveniste, 1997; Aloisi, 2001; Facchinetti et al., 2003 ).  As a response to 
infection or injury, microglia transition from a resting state to a fully activated state that 
is characterized by a morphological remodeling from a ramified shape with long 
processes to an ameboid shaped with contracted processes (Ebert et al., 2005; Rock et al., 
2004; Blasi et al., 1990).  Microglia express antigens that are commonly expressed in 
macrophages, including CD11b, F4/80 and leukocyte common antigen (CD45).  Resident 
microglia transition from a resting to a fully activated state in a multi-step process that 
can be replicated in vitro.  Resting microglia become responsive phagocytes upon 
infection and/or injury, at which time they proliferate and migrate to the site of infection 
or injury.  Other immune cells respond to the infection and/or injury, and secrete 
mediators such as interferon-gamma (IFN-γ) that prime microglia for antigen processing 
and presenting.  Antigens such as bacterial lipopolysaccharide (LPS) can then drive these 
cells to a fully activated state, in which they secrete the pro-inflammatory cytokines 
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interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNF-α); chemokines such as interleukin-8 (IL-8/CXCL8), 
macrophage inflammatory protein-1 alpha (MIP-1α/CCL3) and beta (MIP-1β/CCL4)) 
and regulated on activation, normal T-cell expressed and secreted (RANTES/CCL5); 
reactive oxygen intermediates (ROI); and reactive nitrogen intermediates such as nitric 
oxide (NO) (Table 2) (Franciosi et al., 2005; Qin et al., 2005; Kremlev et al., 2004; 
Arimoto and Bing, 2003; Basu et al., 2002). In addition to morphological modifications 
during this multi-step activation process, Microglia also undergo differential gene 
expression of a host of surface receptors including Fc receptors (Fcγ-RI, RII and RII); 
CD14 receptors; Toll-like receptors (TLR); chemokine receptors (CCR2, CCR3, CCR5, 
CXCR4, CX3CRI); interferon-gamma receptors (IFN-α, β, γ); tumor necrosis factor-
alpha (TNF-α) receptors (TNFRI, TNFRII); and transforming growth factor-beta (TGF-
β) receptors (TGFβ-RI, RII and RII) (63, 65) (Qin et al., 2005; Rock et al., 2004).   
 
Microglial Cell Lines  
   The EOC-20 cells are adherent, immortalized cells derived from the brains of 
normal 10 day old C3H/HeJ mice, and are dependent on colony stimulating factor 1 
(CSF-1) (Walker, 1994).  Comparable to brain macrophages, EOC-20 cells display 
phagocytic activity, IFN-γ-inducible expression of major histocompatibility complex 
(MHC) II (Walker et al., 1995), and can be used as an in vitro cell model to investigate 
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the role of microglia or brain macrophages within the CNS, specifically their immune 
responses upon activation.   
 BV-2 cells were generated by immortalizing primary mouse microglia through 
infection with the v-raf/v-myc oncogene carrying J2 retrovirus (Blasi et al., 1990).  These 
cells possess functional and phenotypic properties common to primary microglial, 
including phagocytic ability, secretion of pro-inflammatory cytokines and expression of 
surface receptors and antigens.  These cells have been used extensively as in vitro models 
to study microglial function, immune responses and the role of microglia in 
neurodegenerative diseases.  BV-2 cells have been shown to become activated upon 
exposure to IFN-γ (Han et al., 2002; Hwang et al., 2004) and LPS (Blasi et al., 1990; Kim 
et al., 2004; Kremlev et al., 2004, Lau et al., 2007). BV-2 cells have been employed to 
study the effects of anti-inflammatory agents on pro-inflammatory cytokine and iNOS 
gene expression (Kim et al., 2004; Lau et al., 2007), and to study the expression profiles 
of chemokines and chemokine receptors upon microglial activation (Kremlev et al., 
2004).    
 
Neuroinflammation 
 The blood brain barrier affords the brain protection from the peripheral 
environment, and microglial maintain immunological homeostasis within the brain 
through production and elicitation of neurotropic factors that promote neuronal survival.  
However, activated microglia have been associated as a direct cause of, or a contributor 
to, exacerbation of a multitude of chronic neurodegenerative diseases that are 
 9
characterized pathologically by an atypical production of pro-inflammatory factors.  
Elicitation of pro-inflammatory and other neurotroxic factors from other cells in the CNS, 
such as astrocytes and perivascular macrophages, and from peripheral immune cells that 
have penetrated the BBB, contributes to the pathology of neurodegenerative and 
neuroinflammatory diseases (Perry, 2004; Gonzalez-Scarano and Baltuch, 1999).  These 
chronic diseases include Alzheimers disease (AD), multiple sclerosis (MS) and human 
immunodeficiency virus encephalitis (HIVE) (Cabral and Marciano-Cabral, 2005; 
Ramirez et al., 2005a; Arevalo-Martin et al., 2003; Arimoto and Bing, 2003; Facchinetti 
et al., 2003; McGreer and McGreer, 2003) (Table 3).  AD is a very common 
neurodegenerative disorder that leads to senile dementia.  The pathological hallmark of 
this disease is the presence of extracellular neuritic amyloid plagues and intracellular 
neurofibrillary tangles (NFTs) that are accompanied by activated microglial and 
astrocytes.  MS is a chronic inflammatory disease that is characterized by T-cell-
mediated demyelination of axonal myelin sheaths that protect axons.  MS patients suffer 
from cognitive impairment, muscle weakness, and impaired coordination, balance, 
speech and sight.  HIVE, also referred to as Acquired Immune Deficiency Syndrome 
(AIDS)-dementia complex, is a neuroinflammatory disorder caused by the production of 
pro-inflammatory cytokines and neurotoxins, such as glutamate and reaction oxygen 
species (ROS), elicited by HIV-infected monocytes and microglia.  In the 
neuroinflammatory diseases described above, there is a failure in maintaining the 
immunological and overall homeostatic balance within the brain, and activated microglia 
play a critical role in this imbalance. 
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Cannabinoid-Mediated Immune Modulation                                                             
 The immune modulatory effects of endocannabinoids and exogenous 
cannabinoids such as ∆9-THC have been well documented.  In the 1970s, a few studies 
suggested that marijuana use was associated with an increased incidence of viral infection 
and implied that cannabinoids suppressed immune resistance to such microbes as Friend 
leukemia virus, herpes simplex viruses (HSV), Acanthamoeba, Listeria monocytogenes, 
Staphylococcus albus, Treponema pallidum and Legionella pneumophila (Cabral and 
Staab, 2005; Morahan et al., 1979; Juel-Jensen, 1972; Cabral and Dove-Pettit, 1998; 
Arata et al., 1991; Arata et al., 1991; Marciano-Cabral et al., 2001, Newton et al., 1994; 
Klein et al., 1998b).  Exogenous cannabinoids have been shown to suppress both cell-
mediated and humoral immune responses in a wide array of immune cells.  ∆9-THC 
suppressed the antibody response of B-cells (Carayon et al., 1998; Friedman et al., 1991; 
Kaminski et al., 1994), and diminished B and T cell proliferation in response to cell-
specific mitogens (Carayon et al., 1998; Derocq et al., 1995).  Both ∆9-THC and 
CP55940 prevented macrophage cell-contact dependent cytolysis of tumor cells 
(Burnette-Curley et al., 1993; Burnette-Curley and Cabral, 1995), while ∆9-THC lessened 
the cell-killing activity of NK cells (Massi et al., 2000).  In addition, ∆9-THC and 
CP55940 have been shown to affect chemotaxis to sites of infection and/or injury 
(Raborn et al., 2008; Sacerdote et al., 2000), and this modulatory affect was demonstrated 
in a mouse model of granulomatous amoebic encephalitis (GAE), where migration to the 
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site of infection was decreased in ∆9-THC-exposed macrophages and macrophage-like 
cells (Marciano-Cabral et al., 2001; Cabral and Marciano-Cabral, 2004).    
Through their interactions with cannabinoid receptors, the immune modulatory 
effects of cannabinoids are down-stream consequences of the inhibition of adenylate 
cyclase activity (Howlett and Fleming, 1984; Howlett, 1985; Howlett et al., 1986; 
Kaminski et al., 1994).  A significant downstream effect of cannabinoid signaling is the 
modulation of gene expression of pro-inflammatory mediators.  In LPS- stimulated 
microglia, ∆9-THC has been shown to inhibit pro-inflammatory cytokine (IL-1α, IL-1β, 
IL-6 and TNF-α) mRNA expression, as well as ablate TNF-α release (Puffenbarger et al., 
2000; Facchinetti et al., 2003).  In astrocytes and other immune cells such as 
macrophages, ∆9-THC, WIN55,212-2 and CP55940 have been shown to inhibit 
production of nitric oxide (NO) (Coffey et al., 1996; Jeon et al., 1996; Waksman et al., 
1999; Molina-Holgado et al., 2002, Ross et al., 2000).  Because cannabinoids can inhibit 
expression of pro-inflammatory mediators, they have therapeutic potential for 
neuropathies characterized by chronic elicitation of these factors.  The therapeutic 
benefits of cannabinoids have been demonstrated both in in vitro and in vivo models of 
MS and AD.  Treatment with the synthetic cannabinoid agonist WIN55,212-2 and HU-
210 improved motor function in Theilers murine encephalomyelitis virus (TMEV)-
infected mice (Croxford and Miller, 2003; Arevalo-Martin et al., 2003), a model of 
chronic demyelinating disease that resembles MS.  These same cannabinoid agonists 
were shown to prevent microglial activation and cognitive impairment in AD based on 
examination of brain samples and primary microglial (Ramirez et al., 2005a).  Thus, 
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using cannabinoid receptors as molecular targets, one may be able to ablate the various 
neuropathological processes associated with improper management of chronic brain 
inflammation.    
 
Nuclear Factor for Kappa Light Chain in B cells (NFκB)  
NFκB is a universal transcription factor involved in a plethora of host regulatory 
immune and inflammatory responses that involve the induction of cytokines, growth 
factors, adhesion molecules, immunoreceptors and acute-phase  proteins (Sancho et al., 
2003; Ghosh and Karin, 2002; Vermeulen et al., 2002; Lawrence et al., 2001; Herring 
and Kaminski, 1999; Ghosh et al., 1998; Tzen et al., 1994; Blackwell and Christman, 
1997).  NFκB, first identified in 1986 (Sen and Baltimore, 1986), belongs to the Rel 
family of proteins, and in mammals can be composed of homo- and hetero- dimmers of 
the subunits p65 (Rel A), Rel B, c-Rel, p50/p105 (NFκB1) and p52/p100 (NFκB2).  The 
classical NFκB protein is the p65/p50 hetereodimer which plays a critical role in acute 
inflammatory responses by up-regulating the transcription of pro-inflammatory cytokine 
and chemokine genes, including IL-1α, IL-1β, IL-6, TNF-α, IL-8 and macrophage 
inflammatory protein-1 (MIP-1) and RANTES (Blackwell and Christman, 1997; 
Lawrence et al., 2001; Ye and Johnson, 2001).  As members of the Rel family, NFκB 
proteins have an N-terminal Rel homology domain (RHD) that is involved in DNA 
binding, dimerization, IκB inhibitor interaction and nuclear translocation. The p65, Rel B 
and c-Rel subunits have a C-terminal activation domain that is involved in transcriptional 
activation, and this domain interacts directly with the cellular basal transcription 
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apparatus (Blackwell and Christman, 1997; Schmitz and Baeuerle, 1991) (Figure 1).  The 
p105 and p100 precursor subunits have C-terminal ankyrin repeat motifs that can be 
cleaved by the ubiquitin-proteasome system to generate the p50 and p52 subunits, 
respectively (Orian et al., 1995) (Figure 1).   
Activation of NFκB is stringently regulated both intracellularly and 
extracellularly.  In unstimulated cells, NFκB is retained in the cytoplasm by the masking 
of its nuclear localization signal (NLS) by the IκB family of inhibitor proteins.  This 
family of proteins consists of IκBα, IκBβ, IκBε, IκBγ/p100, IκBζ/p105, and Bcl3.  These 
proteins are tissue-specific, and have variable affinities for the different NFκB dimers 
(Gilmore, 2006).  IκB proteins consist of ankyrin repeat motifs with two N-terminal 
serine residues (Figure 1), and these structural features allow IκB proteins to bind to 
NFκB, and to be phosphorylated and degraded upon stimulus-induced cell activation.  
The major inhibitor of the p65/p50 NFκB heterodimer is the IκBα protein (Tergaonkar, 
2006; Li and Stark, 2002; Karin and Neriah, 2000).  Homodimers of p105 or p100 
subunits can act as inhibitors through direct interaction with the RelA subunit.  There are 
various activators of the classical form of NFκB signaling including the pro-
inflammatory cytokines IL-1 and TNF-α, growth factors, viruses, and most notably the 
bacterial antigen LPS. LPS binds to the serum protein LPS-binding protein (LBP), which 
facilitates binding to CD14, a cell surface receptor found on monocytes and neutrophils 
(Wright et al., 1990).  LPS/LBP complexes bind CD14, which acts in concert with Toll-
like receptors (TLR) such as TLR-4 and TLR-2 to activate cells and activate NFκB 
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(Ghosh et al., 1998, Ghosh and Karin, 2002; Pomerantz and Baltimore, 2002; Yamamoto 
and Gaynor, 2004).  Upon cell activation, IκBα is phosphorylated at serine residues 
Ser32 and Ser36 by several kinases including cAMP-dependent protein kinase (PKA) and 
the IκB kinases (IKK), and the phosphorylated protein serves as a recognition marker for 
the β-TrCP-containing SCF ubiquitin ligase complex (Li and Stark, 2002).  The 
ubiquitinated protein is then recognized by the 26S proteasome that degrades IκBα.  
IκBα makes multiple contacts with NFκB and its degradation not only allows for NFκB 
translocation into the nucleus, but also allows for kinase-specific phosphorylation of the 
p65 subunit at serine residues Ser276, Ser529 and Ser539 (Sasaki et al., 2005; Wang and 
Baldwin, 1998; Wang et al., 2000; Sakurai et al., 2003; Sakurai et al., 1999; Sizemore et 
al., 2002; Yang et al., 2003).  Serine residues 529 and 536, located in the transactivation 
domain of p65, are phosphorylated by casein kinase (CSK) II and IKK, respectively.  
Serine 276 is located in the Rel homology domain and is phosphorylated by PKA.  Serine 
residues 536 and 276 are phosphorylated upon TNF-α or LPS stimulation.  The events 
that lead to the degradation of IκBα, and the termination of NFκB sequestration act in 
concert to allow nuclear translocation and recognition and binding to the DNA consensus 
sequence 5-GGGACTTTCC-3 located in the promoter regions of pro-inflammatory 
cytokine and chemokine genes.    
Although its activation is tightly regulated, improper regulation of NFκB has been 
linked to inflammatory and autoimmune diseases such as asthma, rheumatoid arthritis, 
and Alzheimers disease (Yamamoto and Gaynor, 2004).  Alveolar macrophages of 
patients suffering from adult respiratory distress syndrome (ARDS) have been shown to 
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have increased levels NFκB, that were linked to an increase in the production of IL-8 and 
TNF-α (Miller et al., 1992; Hyers et al., 1991).  In another study, rats were subjected to 
intraperitoneal injections (IP) of endotoxin, which caused an increase in NFκB levels in 
alveolar macrophages and lung tissue (Blackwell et al., 1994; Blackwell, 1996).  This 
increase in NFκB correlated to an increase of mRNA expression for cytokine-induced 
neutrophil chemoattractant (CINC); however, blocking endotoxin induction of NFκB led 
to a decrease in CINC mRNA expression and lung inflammation (Blackwell et al., 1994; 
Blackwell et al., 1996).  In a rat model of autoimmune encephalomyelitis, an animal 
model widely used to investigate MS, microglial cells isolated from these animals were 
shown to have elevated levels of NFκB activation (Kaltschmidt et al., 1994).   
There are several inhibitors of NFκB activation, including antioxidants, protease 
and proteasome inhibitors and glucocorticoids and corticosteroids (Epinant and Gilmore, 
1999), whose mechanisms of action include suppressing phosphorylation of IκB proteins 
(Cho et al., 1998; Schreck et al., 1992b), inhibiting degradation of IκB proteins (Grisham 
et al., 1999; Jobin et al., 1998a; Palombella et al., 1994) and preventing the 
transactivation of NFκB (Auphan et al., 1995; Brostjan et al., 1996; Ray and Prefontaine, 
1994; Scheinman et al., 1995), respectively.  
 Cannabinoids are believed to behave as anti-inflammatory agents due to their 
inhibitory effects on mRNA expression of pro-inflammatory cytokines.  The critical 
question that we wish to answer in these studies is, can appropriately engineered 
cannabinoids, devoid of any psychotropic properties, have the potential to be therapeutic 
agents for neuroinflammatory diseases that are pathologically hallmarked by a chronic 
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elicitation of pro-inflammatory mediators?  This task may be feasible when considering 
that highly lipophilic cannabinoids can readily pass through the BBB, and act through 
specific receptors.  While cannabinoids have been shown to down-regulate the inducible 
gene expression of pro-inflammatory mediators, the exact mechanism(s) of this down-
regulation have yet to be fully elucidated, specifically in microglial.  The overall goal of 
this investigation was to define the mechanism(s) in which cannabinoids down-regulate 
the gene expression of pro-inflammatory mediators in microglia.  It was postulated that 
cannabinoid-mediated down-regulation of cytokine gene expression may take place at the 
promoter and/or transcriptional level by modulating the activity of transcription factors, 
such as NFκB, that play a critical role in inducing the inflammatory immune response.  
Three specific aims were established in order to test this hypothesis.  The first specific 
aim was to define the effects of ∆9-THC and CP55940 on the binding of NFκB to its 
cognate consensus sequence and its transcriptional activity.  The second specific aim is to 
define the specificity of action in which ∆9-THC and CP55940 modulates NFκB activity.  
With this aim, we asked whether effects are mediated through the CB1, the CB2 or 
another mechanism that is not specific for either cannabinoid receptor (Non CB1/ CB2).  
Lastly, the third specific aim was to define the site of action in which ∆9-THC and 
CP55940 modulate NFκB activity.  We assessed the effects of both exogenous 
cannabinoids on critical regulatory steps of NFκB activation in both the cytoplasm and 
nucleus.  
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    A. RelA (p65), RelB, c-Rel 
 
 
   B. p105/p50, p100/p52 
 
 
   C. IκB- α, β, ε, γ(p100), ζ(p105) 
 
 
 
 
 
 
Figure 1. Structure of NFκB and IκB Proteins. (A), The Rel subfamily- RelA(p65), 
RelB and c-Rel. The N-terminal domain has the Rel homology domain (RHD) that 
aids in dimerization, DNA and IκB binding, and nuclear translocation. The C-
terminal domain contains the transactivation domain (TAD) that interacts directly 
with the cellular transcription apparatus. (B), The NFκB subfamily- p105/p50 and 
p100/p52 proteins. The N-terminus also has a RHD, but its C-terminal domain has 
ankyrin repeat motifs that are recognized by the ubiquitin-proteasome system.  The 
degradation of the ankyrin motifs generates the p50 and p52 subunits, respectively.  
The C-terminus also has two serine residues that can be phosphorylated by serine 
kinases.  (C), The IκB family of proteins, IκB- α, β, ε, γ, and ζ.  IκB proteins are 
mainly ankyrin repeat motifs with two serine residues that are required for 
proteolytic degradation and phosphorylation, respectively.   
Abbreviations: RHD = Rel homology domain; TAD = transactivation domain;       
SS = serine residues; solid stripes = ankyrin repeats. 
 
Adapted from Gilmore, T.D., 2006
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SS 
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Table 1- Receptor-linked G Proteins 
 
 
G-protein Subtype Signaling  Effects Second Messenger 
Gs ↑ adenylate cyclase (AC) cAMP 
 ↑ Ca2+ channel Ca2+ 
 ↓ Na2+ channel ∆ in membrane potential 
   
Gi ↓ adenylate cylcase (AC) cAMP 
 ↑ K+ channel ∆ in membrane potential 
 ↓ Ca2+ channel Ca2+ 
   
Gq ↑ phospholipase C (PLC) IP3, DAG 
   
Go ↑ phospholipase C (PLC) IP3, DAG 
 ↓ Ca2+ channel Ca2+ 
   
Gt ↑ cGMP phosphodiesterase cGMP 
   
Gβγ ↑ phospholipase (PLC) IP3, DAG 
 ↓ adenylate cyclase (AC) cAMP 
 
Abbreviations: ∆ = change; AC = adenylate cyclase; cAMP = cyclic adenosine 
monophosphate; cGMP = cyclic guanosine monophosphate; DAG = diacylglycerol; 
Ca2+ = calcium ion; IP3 = inositol triphosphate; K+= potassium ion; Na2+ = sodium 
ion; PLC = phospholipase C. 
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Table 2- Pro-Inflammatory Mediators 
 
Abbreviations: iNOS = inducible nitric oxide synthase. 
 
 
Cytokine/Chemokine Description 
Interleukin-1 alpha/beta 
(IL-1α/β) 
Inflammatory cytokines  produced by macrophages, 
monocytes and dendritic cells. 
 Induces NFκB activation.  
 Increases expression of adhesion molecules. 
 Endogenous pyrogen  induces fever during infection. 
  
Interleukin-6 (IL-6) Inflammatory cytokine. 
 Produced by T-cells and macrophages. 
 Mediator of fever during the acute phase response. 
  
Tumor Necrosis Factor-
alpha (TNF-α) 
Inflammatory cytokine  plays critical role in sepsis.  
Stimulates the acute phase response. 
 Produced by macrophages and a host of other cell types. 
 Induces apoptosis and inhibits tumorigenesis. 
 Associated with inflammatory disorders. 
  
Nitric Oxide (NO) Chemical messenger molecule  synthesized by iNOS. 
 Produced by macrophages, monocytes and neutrophils.  
 Induces production of pro-inflammatory cytokines. 
 Associated with various inflammatory diseases.  
  
Macrophage Inflammatory 
Protein-1 (MIP-1) 
Inflammatory chemokine  2 subtypes, alpha (CCL3) 
and beta (CCL4). 
 Produced by endotoxin-induced macrophages. 
 Activates neutrophils, basophils and eosinophils. 
 Associated with neutrophilic inflammation. 
 Induces production of pro-inflammatory cytokines. 
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Table 3- Neuroinflammatory Disorders 
 
 
Disease Symptoms/Pathology Cannabinoid Effects 
AD Neurodegenerative disorder; Causes senile 
dementia; Extracellular amyloid plaques; 
Intracellular neurofibrillary tangles. 
Inhibits microglial activation; 
Prevents/rescues blood 
lymphocytes from apoptosis. 
   
MS  Chronic demyelinating disease; T-cell 
mediated degeneration of axonal myelin 
sheaths; Causes motor deficits and/or 
paralysis.  
Improves neurological 
deficits; Reduces microglial 
activation and T-cell 
infiltration. 
   
ALS  Progressive degeneration of cortical motor 
neurons; Causes musle wasting, weakness 
and spasticity; complete paralysis. 
Delays onset of symptoms and 
disease progression. 
   
HIVE Chronic brain inflammation; Causes 
impaired memory, intellect and motor 
function; Neuronal loss; Persistent 
microglial activation. 
Inhibits activation of the HIV 
co-receptor CCR5; CB2 
activation inhibits 
transendothelial T-cell 
migration. 
 
Abbreviations: AD = Alzheimers Disease; MS = Multiple Sclerosis; ALS = 
Amyotropic Lateral Sclerosis; HIVE = Human Immunodeficiency Virus 
Encephalitis. 
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Materials and Methods 
 
 
 
Drugs and Reagents 
 
 The studies performed for this project included the use of plantonic and synthetic 
exogenous cannabinoid agonists and antagonists (Table 4).  The partial CB1/CB2 receptor 
agonist delta-9-tetrahydrocannabinol (∆9-THC; CB1 Ki = 40.7 nM; CB2 Ki = 36.4 nM) 
was obtained from the National Institute on Drug Abuse (NIDA) (Rockville, MD).  The 
CB1/CB2 receptor full agonist CP55940 (CB1 and CB2 Ki = 1.4 nM) and CB2 selective 
agonist O-2137-2 (CB1 Ki = 2700 nM, CB2 Ki = 11 nM) were provided by Dr. Billy R. 
Martin (Department of Pharmacology and Toxicology, Virginia Commonwealth 
University).  CP55940 was also purchased from Tocris Cookson (Ballwin, MO).  The 
CB1 selective agonist ACEA (arachidonyl-2-chloroethylamide) (CB1 Ki = 1.4 nM, CB2 
Ki = > 2000 nM) was purchased from Tocris Crookson in addition to CP55940.  The CB1 
selective antagonist SR141716A (CB1 Ki = 2 nM, CB2 Ki > 1000 nM) and the CB2 
selective antagonist SR144528 (CB1 Ki = 437 nM, CB2 Ki = 0.6 nM) were obtained from 
Sanofi Recherche (Montpellier, France).  Stock solutions of cannabinoids at 10-2M were 
prepared in 100% ethanol and stored at -20°C.  Stock solutions were diluted in complete 
growth medium to generate working concentrations used in experimental studies with a  
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Table 4- Selected Cannabinoid Receptor Ligands 
 
 
Ligands                  Receptor Selectivity           Dissociation Constant (Ki) 
                                                                               CB1 Ki          CB2 Ki 
 ∆9-THC                        CB1/CB2 partial agonist                 40.7 nM             36.4 nM 
 
 CP55940                      CB1/CB2 full agonist                      1.37 nM             1.37 nM 
 
 ACEA                          CB1 selective agonist                     1.4 nM               >2000 nM 
 
 O-2137                         CB2 selective ligand                       2700 nM             11 nM 
 
SR141716A (SR1)        CB1 selective antagonist                11.8 nM              13200 nM 
 
SR144528 (SR2)           CB2 selective antagonist                437 nM               0.6 nM 
 
O-2095                          Non CB1/CB2 selective agonist      8700 nM            8800 nM 
 
Abbreviations: ∆9-THC = delta-9-tetrahydrocannabinol; CP55940 = ((-)-cis-3-(2-
Hydroxy-4-(1,1-dimethylheptyl)phenyl)-trans-4-(3-hydroxypropyl) cyclohexanol); 
ACEA = (N-(2-Chloroethyl)-5Z,8Z,11Z,14Z- eicosatetraenamide); O-2137 = 
((1R,3R)-1-(4-(1,1-Dimethylheptyl)- 2,6-dimethoxyphenyl)-3-methylcyclohexanol); 
SR141716A = (5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1-
piperidyl)pyrazole-3-carboxamide); SR144528 = ((1S-endo)-5-(4-Chloro-3-methyl-
phenyl)-1-((4methylphenyl)methyl)-N-(1,3,3-trimethylbicyclo(2.2.1)hept-2-yl)-1H-
pyrazole-3-carboxamide); O-2095 = 1-Norarachidonyl-3-(2-hydroxyethyl)urea.  
 
Adapted from Howlett et al., 2002; Ng et al., 1999 
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final ethanol concentration of 0.01%. The vehicle control consisted of 0.01% ethanol in 
complete growth medium. 
For cell activation, we utilized bacterial lipopolysaccharide (LPS) from 
Escherichia coli strain 0127:B8, purchased from Sigma Aldrich (St. Louis, MO).  A  
stock solution of 1mg/ml was made in complete growth medium and stored at -20°C.  
Working solutions of 0.1µg/ml were made from dilution of the stock solution for all 
experiments. 
 
 
Cell Culture 
  
The EOC-20 cells were purchased from American Type Tissue Culture (ATCC) 
(Manassas, VA).  Cell cultures were maintained at 37°C with 5% CO2 in ventilated T-
175 flasks in complete  Dulbeccos Modified Eagles Medium (DMEM) (Mediatech, 
Herndon, VA) supplemented with 1% each of L-glutamine, non-essential amino acids, 
and MEM vitamins, 0.01M HEPES buffer, penicillin (100 IU/ml)/streptomycin (100 
µg/ml)/ amphotericin B (0.25 µg/ml), 20% LADMAC-conditioned media and 10% heat-
inactivated fetal bovine serum (HI-FBS).  The complete growth medium was 
supplemented with LADMAC-conditioned media for a source of colony stimulating 
factor-1 (CSF-1), which EOC-20 cells require for proper growth.  Confluent monolayers 
of EOC-20 cells were scraped from the culture flasks using rubber cell scrapers. 
LADMAC cells, transformed cells derived from mouse bone marrow cells that 
constitutively secrete the CSF-1 growth factor, were maintained in complete Eagles 
Minimal EssentialMedium (EMEM) at 37°C with 5% CO2 in ventilated T-175 flasks.  To 
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harvest LADMAC-conditioned media, confluent cell suspensions were centrifuged, and 
the supernatants were collected and sterile filtered.  The conditioned media then were 
stored at -20°C until used in experiments. 
The BV-2 cell line (obtained from Dr. Michael McKinley, Mayo Clinic, 
Jacksonville, FL) is an immortalized murine primary microglia line generated through 
infection with a v-raf/v-myc oncogene carrying J2 retrovirus (Blasi et al., 1990).  Cell 
cultures were maintained at 37°C with 5% CO2 in ventilated T-175 flasks in complete 
Dulbeccos Modified Eagles Medium (DMEM) (Mediatech, Herndon, VA) 
supplemented with 1% each of L-glutamine, non-essential amino acids, and MEM 
vitamins, 0.01M HEPES buffer, penicillin (100 IU/ml)/streptomycin (100 µg/ml)/ 
amphotericin B (0.25 µg/ml) and 10% heat-inactivated fetal bovine serum (HI-FBS).  For 
use in in vitro experiments, confluent BV-2 cells were detached from culture flasks with 
Cellstripper (Mediatech, Herndon, VA), a non-enzymatic detachment buffer.   
 
Isolation of Primary Microglia 
Primary microglia cultures were prepared using neonatal Sprague-Dawley 1-2 
day-old rat pups (Zivik-Miller Laboratory, Zeleinople, PA).  The rat pups were sacrificed, 
and the cerebral cortices were isolated and dissected in dissection saline (2.8% (v/v) stock 
dissection HEPES (352 mM HEPES); 5% (v/v) stock dissection saline (137 mM NaCl, 
5.3 mM KCl, 0.17 mM Na2PO4-7H2O, 0.22 mM KH2PO4, and 0.0012 g/L Phenol red); 5% 
(v/v) stock glucose/sucrose solution (6 g/L glucose, 15 g/L sucrose); and 
penicillin/streptomycin (100 U/ml)).  The meninges surrounding the cortices were 
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removed, and the tissues were trypsinized and manually homogenized in porcine 
pancreas-derived trypsin (Sigma) for 10 min.  The trypsinization was terminated upon the 
addition of complete DMEM, and the homogenized tissue was filtered through a 70 µm 
BD Falcon nylon cell strainer (BD Biosciences, San Jose, CA).  The filtered cell 
suspension was centrifuged at 212 x g for 30 min. at 4°C.  The mixed glial culture 
consisting of astrocytes and microglial were seeded in T175 cm2 culture flasks (Greiner, 
Monroe, NC), and incubated at 37°C with 5% CO2.  The complete DMEM was dumped 
the following day, and fresh complete DMEM was added to the flasks, at which time the 
cultures were allowed to grow for 14-21 days.  To isolate primary microglia, the 
astrocyte-microglia cultures were shaken at 180 rpm on an orbital shaker for 2 h at room 
temperature. 
 
Cell Treatment 
Detached EOC-20 and BV-2 cells were collected in sterile 50 ml conical tubes, 
centrifuged (170 x g; 1000 rpm) for 8 min., resuspended, and seeded in complete DMEM 
at 1 x 106cells/ml and 7 x 105cells/ml, respectively.  The seeded cells were incubated 
overnight to allow for attachment.  The following day, cells were pre-incubated for 3 h 
with ∆9-THC or CP55940 (10-5M to 10-10M) and stimulated with 100 ng/ml LPS for 
specified times.  For experiments with cannabinoid receptor-specific antagonists, cells  
were treated for 1 h with SR141716A or SR144528 (10-6M), treated for 3 h with 
CP55940 or ∆9-THC (10-7M) , and then stimulated with 100 ng/ml LPS for specified 
times.  In additional experiments, cells were stimulated with various concentrations of 
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TNF-α (10 ng/ml  100 ng/ml) or IFN-γ (50 U/ml or 100 U/ml) for various time periods.  
Each experiment included vehicle (0.01% ethanol) and LPS/vehicle control groups.  At 
the conclusion of experiments, the treatment medium was discarded and replaced with ice 
cold 1X phosphate buffer saline (PBS) containing 0.5X phosphatase inhibitor.  Cell 
suspensions were centrifuged (170 x g) for 5 min. at 4°C in 1.5 ml conical tubes.  Cell 
pellets were subjected to whole protein or cytoplasmic and nuclear protein extraction or 
stored at -80°C until needed. 
 
Isolation of Plasmid Contructs  
 CB1 and CB2 DNA served as the positive controls in all Real-Time RT-PCR assays, 
and was isolated from expression vectors containing the DNA sequence for each 
cannabinoid receptor.  The CB1 plasmid pCD-rSKR6 was a gift from Dr. L. Matsuda 
(Medical University of South Carolina, Matsuda et al., 1990), and the CB2 plasmid 
pUC18-mCB2 was a gift from Dr. T. Bonner (NIMH, Bethesda, MD).  DH5α E. coli 
cells transformed with the pCD-rSKR6 vector were cultured in 10 ml of Luria Bertani 
(LB) broth (10 g Bacto-tryptone; 5 g yeast extract; 10 g NaCl per liter) containing 100 
µg/ml ampicillin (amp), and the isolated plasmid was prepared using the Midi Prep Kit 
(Qiagen, Valencia, CA).  Similar methods were applied to isolate and prepare the pUC18-
mCB2 plasmid using Qiagens Midi Prep Kit.  Both vectors were digested with BamHI 
and EcoRI restriction enzymes to release 2.4 kb and 1.3 kb DNA fragments for CB1 and 
CB2, respectively (Figure 2).  The DNA fragments were gel extracted from a 1.5% 
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agaraose gel using the QIAquick Gel Extraction Kit (Qiagen), and stored at -20°C in 
DNase-free dH2O. 
 
Real-Time Reverse Transcriptase-PCR (RT-PCR)  
 Real-Time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) was 
carried out to assess for the presence of CB1 and CB2 mRNA.  Constitutive mRNA 
expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was assayed as the 
housekeeping control.  Total RNA was prepared from BV-2 cells using TRIzol reagent 
(Invitrogen) according to manufacturers instructions.  Chloroform/isopropanol extraction 
was used to isolate the RNA which then was resuspended in 50 µl of PCR grade water.  
Residual genomic DNA was removed from the isolated RNA by RNase-free DNase I 
Amplification grade (Invitrogen) treatment.  The initial step in the reverse transcription of 
isolated RNA into cDNA was carried out in a 13 µl reaction volume according to the 
Superscript III RT kit instructions (Invitrogen), using 1 µg of DNase-treated RNA, 50 
ng/µl of random hexamers and 10 mM of dNTP mix.   The reaction mixture was heated 
to 65°C (5 min.) and cooled to 4°C in a Biorad MyCycler (Biorad, Richmond, CA).  The 
cDNA synthesis was performed in a 23 µl reaction mixture containing the RNA/random 
hexamer/dNTP mixture, 1X RT-PCR buffer, 10 mM MgCl2, 20 mM DTT, 40 U of 
RNaseOUT (Invitrogen) and 200 U of Superscript III reverse transcriptase.  DNA 
synthesis was carried out under the following conditions: (25°C, 10 min.; 50°C, 50 min.;  
85°C, 5 min.; and 4°C, 1 min.).  Real-Time PCR was performed in a Cepheid 
(Sunnyvale, CA) Smart Cycler using a SYBR green PCR mix (SuperArray).  The 
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fluorescent stainSYBR green binds nucleic acid and displays a greater binding affinity for 
double-stranded DNA which heightens the fluorescent signal.  Amplification was 
performed in a 25 µl reaction mixture consisting of 12.5 µl of Syber green mix, 1 µl of 
primer mix for the murine CB1 gene (Cnr1: PPM04603A), 2 µl of cDNA and 9.5 µl of 
PCR grade water.  A similar approach was applied to assess for CB2 mRNA, using a 
primer mix for the mouse CB2 gene (Cnr2: PPM04826A).  Reaction mixtures were 
pipetted into Smart Cycler PCR tubes, and subjected to amplification under the following 
conditions: initial denaturation at 95°C, 15 min.; and 40 cycles of additional denaturation 
at 95°C, 30 sec; annealing at 55°C, 30 sec, and extension at 72°C, 30 sec.  A crossover 
threshold (Ct) of 30 fluorescence units was used as the reference point to measure DNA 
amplification.  A separate reaction mixture using primers for the GAPDH gene (GAPDH: 
PPM02946A) was included as the internal standard.  PCR products were resolved on a 
4% OmniPur agarose (VWR, West Chester, PA) gel.  Using this methodology, the 167 bp 
and 207 bp products of CB1 and CB2, respectively, were amplified. 
 
Cytoplasmic and Nuclear Protein Extraction 
 
Cytoplasmic and nuclear protein fractions were extracted from EOC-20 or BV-2 
cells using a Nuclear Extract Kit (Active Motif, Carlsbad, CA), according to the 
manufacturers protocol. Briefly, cell pellets were resuspended in 150 µl of 1X hypotonic 
buffer and incubated on ice for 15 min.  Detergent then was added and the tubes were  
briefly vortexed and centrifuged (14,000 X g) for 1 min.  The supernatant containing the 
cytoplasmic protein fraction was collected in pre-chilled microfuge tubes and stored at -
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80°C until used in experiments.  The pellet containing nuclei was resuspended in 
complete lysis buffer (1 mM DTT, lysis buffer AM1, protease inhibitor cocktail) and 
incubated on ice for 30 min.  Resuspended nuclei were vortexed briefly and centrifuged 
(14,000 X g) for 10 min. and nuclear protein fractions were collected in pre-chilled 
microfuge tubes and stored at -80°C until used in experiments.  Protein concentrations of 
cytoplasmic and nuclear fractions were determined by Bradford assay (M. M. Bradford, 
1976). 
 
TransAM NFκB ELISA 
 The TransAM NFκB ELISA (Active Motif, Carlsbad, CA) was employed to 
assess for NFκB activation by way of measuring levels of the p65 protein in EOC-20 
cells.  EOC-20 cells were either treated overnight with various concentrations of TNF-α 
(10 ng/ml  100 ng/ml) or treated with 50 U/ml of IFN-γ for various times (0.25 h to 24 
h).  A standard curve was prepared by performing serial dilutions of recombinant p65 
protein (Active Motif).  The stock solution (100 ng/µl) of recombinant p65 was diluted to 
a working solution of 0.5 ng/µl, which was serially diluted to generate 0.5 ng/µl, 0.25 
ng/µl, 0.125 ng/µl, 0.0625 ng/µl, 0.0312 ng/µl, 0.0156 ng/µl and 0.008 ng/µl standards.  
Aliquots of 20 µl for each standard were assayed and correspond to the following 
quantities of p65 per well: 10 ng, 5 ng, 2.5 ng, 1.25 ng, 0.625 ng, 0.312 ng, 0.156 ng and 
0 ng (Figure 5).  Complete lysis buffer served as the negative control (0 ng/well).   
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Experimental samples, and positive, negative, competitor and non-competitor 
control samples were prepared according to the manufacturers instructions.  The 
experimental samples consisted of 10 µg of EOC-20 nuclear protein; the positive control 
consisted of 2.5 µg of Jurkat nuclear extract; and the negative control consisted of 
complete lysis buffer (5 mM DTT, protease inhibitor cocktail, lysis buffer AM2) only.  
All samples were incubated with 30 µl of complete binding buffer (2 mM DTT, Herring 
sperm DNA, binding buffer AM3) for 1 h at room temperature.  The competitor and non-
competitor reactions consisted of 20 pmol of wild-type and mutated consensus 
oligonucleotides, respectively, in addition to the nuclear extract and complete binding 
buffer.  The wells then were washed 3 times in 1X wash buffer AM2, followed by 
incubation with anti-p65 antibody diluted 1:1000 in 1X antibody binding buffer AM2 for 
1 h at room temperature.  After another series of washes, a HRP-conjugated secondary 
antibody diluted 1:1000 was added to each well for 1 h at room temperature.  Following 
incubation with the secondary antibody, colorimetric detection was carried out and the 
absorbance of each sample at 450 nm wavelength was taken using the Spectramax 
spectrophotometer (Molecular Devices, Sunnyvale, CA).          
 
Electrophoretic Mobility Shift Assay (EMSA) 
Mobility shift assays were performed on nuclear protein fractions using the NFκB 
Gel Shift Kit (Active Motif).  Briefly, a wild-type NFκB oligonucleotide probe, 
containing the consensus sequence 5-GGGGATCCC-3, was end-labeled with (γ- 32P) 
ATP, and purified through spin column purification using MicroSpin G-25 columns 
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(Active Motif).  The specific activity of the labeled probe was determined by taking a 
Cerenkov count to confirm an activity of >1 X 105 counts per minute (cpm)/µl.  The 
extract premix consisted of 4 µl of 4X binding buffer B2, 2 µl of 8X stabilizing solution, 
4 µg of nuclear protein and dH2O to a final volume of 16 µl.  The extract premix then 
was incubated at 4°C for 20 min.  For super shift assays, 2 µl of rabbit anti-p65 or anti-
p50 antibody was added to the extract premix.  The probe premix was composed of 2 µl 
of 4X binding buffer C2, 1 µl of 8X stabilizing solution, and 1 µl (≥100,000 cpm) of 32P-
labeled NFκB probe in a total volume of 8 µl.  The extract and probe premixes were 
added together, and the mixture was incubated at 4°C for 20 min.  The cold competitor 
and non-competitor reaction probe premixes contained an excess of unlabeled wild-type 
and mutant NFκB oligos, respectively.  Reaction mixtures were subjected to 
electrophoresis (1 h, 250V) on a native 5% polyacrylamide gel in 1X tris-glycine (TGE) 
buffer.  Gels were vacuum-dried and exposed to X-ray film (PerkinElmer, Boston, MA) 
at -80°C. 
 
NFκB Reporter Activity Assay 
        Transformation of Competent XL-1 Blue E. coli cells 
The reporter plasmids pNFκB-Luc and pSV-β-galactosidase were employed in 
NFκB reporter activity assays.  pNFκB-Luc is a 5.7 kb reporter plasmid (Figure 18)with 
the luciferase (Luc) reporter gene that is driven by a TATA box promoter element and a 
NFκB-specific enhancer element.  The enhancer element contains 5 repeats of the 
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recognition sequence 5-GGGACTTTCC-3.  Upon cell activation, NFκB will bind the 
enhancer element and drive the expression of the Luc gene.  The reporter plasmid pSV-β-
galactosidase (Figure 21) was used as a control plasmid to determine transfection 
efficiency.  This 6.8 kb plasmid has a SV40 early promoter and enhancer that drive 
constitutive expression of the LacZ gene, thus producing the β-galactosidase enzyme.  
Both pNFκB-Luc and pSV-β-galactosidase were transformed into XL-1 Blue E. coli cells 
for long-term use.  XL-1 Blue cells were thawed on ice and aliquoted in 100 µl volumes.  
β-mercaptoethanol was added to each aliquot of cells, and the mixture was incubated for 
10 min. on ice with swirling every 2 min.  The pNFκB-Luc and pSV-β-galactosidase 
plasmids were added separately to the XL-1 Blue cells and incubated on ice for 30 min.  
The cells were heat-pulsed in a 42°C water bath for 45 sec and then incubated on ice for 2 
min.  Super Optimal broth with Catabolite repression (SOC) medium, pre-heated to 42°C, 
was added to the cells, which were then incubated at 37°C for 1 h with gentle shaking.  
The transformation mixture (≤ 200 µl) was plated on LB-agar (10 g Bacto-tryptone; 5 g 
Bacto-yeast extract; 5 g NaCl; 12 g Bacto-agar per liter) plates containing ampicillin 
(amp) (100 µg/ml).  The plates also contained 100 µl of 2% X-gal and 100 µl of 10 mM 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) for blue-white screening.  Cells properly 
transformed with each plasmid will appear as white colonies on the plate, and those that 
are not transformed will appear blue.  The pSV-β-galactosidase transformed cells will 
grow as blue colonies if streaked on agar plates containing only IPTG, due to constitutive 
expression of the β-galactosidase gene.  All plates were stored at 4°C. 
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A Maxi Prep Kit (Qiagen) was used to isolate the pNFκB-Luc and pSV-β-
galactosidase expression vectors.  XL-1 Blue E. coli cells, transformed with both 
expression vectors, were cultured overnight in 250 ml of LB-amp (100 µg/ml) broth.  
Concentrations of all plasmids and DNA fragments were obtained using a Biophotometer 
(Eppendorf, Westbury, NY).  Glycerol stocks of each plasmid were made stored at -80°C.  
Freshly streaked LB-amp agar plates with the pNFκB-Luc and pSV-β-galactosidase 
cultures were sent to the Molecular Biology Core Facility (Virginia Commonwealth 
University) for plasmid isolation.  Maxi plasmid preparations were performed as 
described previously.  The isolated pNFκB-Luc and pSV-β-galactosidase plasmids were 
restriction-enzyme digested with EcoRV and/or EcoRI.  The digested plasmids were 
electrophoresed on a 1.5% agarose gel to reveal the linearized pNFκB-Luc and pSV- β-
galactosidase plasmids (See Figures 19 and 22). 
 
 Transient Transfection/Luciferase Assay 
  To assay for NFκB transcriptional activity, BV-2 cells were transiently 
transfected with the pNFκB-Luc reporter plasmid (Stratagene, La Jolla, CA) using 
TransIT-Neural® transfection reagent (Mirus, Madison, WI).  To normalize results from 
luciferase measurements, cells were co-transfected with pSV-β-galactosidase control 
plasmid (Promega, Madison, WI).  BV-2 cells were seeded at 2 X 105cells/ml to achieve 
50-70% confluency, and incubated overnight at 37°C with 5% CO2.  The transfection 
mixture per sample was prepared as follows: 6 µl of TransIT-Neural® reagent were added 
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to 250 µl of serum-free growth medium and the mixture was incubated for 20 min. at 
room temperature to allow for complex formation.  Five micrograms (µg) of pNFκB-Luc 
and 5 µg of pSV-β-galactosidase plasmids were mixed together, and added to the 
transfection reagent/serum-free medium solution.  The mixture was allowed to incubate 
for an additional 10 min. at room temperature.  The transfection mixtures were added 
dropwise to each cell culture plate, and transfection was allowed to occur overnight at 
37°C with 5% CO2.  Following transient transfection, the transfection medium was 
removed, and cells were pre-treated with drug or vehicle for 3 h and stimulated with 100 
ng/ml LPS for 3 h.  Cells then were lysed, and luciferase and beta-galactosidase activity 
was assayed using the Dual-Light® Luciferase and β-Galactosidase Reporter Gene Assay 
System (Applied Biosystems, Bedford, MA) with an Orion Microplate Luminometer 
(Berthold Detection Systems, Oakridge, TN).    
 
Whole Cell Protein Extraction 
Whole cell protein lysates of BV-2 cells were used in some Western blot assays.  
After drug treatment and stimulation, BV-2 cells were washed 2 times with room 
temperature 1X PBS.  The cells were scraped from the culture flasks, collected and 
centrifuged at 400 x g for 10 min.  The supernatant was aspirated and the cell pellets were 
resusupended in cold lysis buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl and 1% NP-
40) containing 1X protease inhibitor cocktail (Sigma).  The resuspended cells were gently 
vortexed and incubated on ice for 30 min. with occasional mixing.  The lysed cells were 
centrifuged at 10,000 x g for 15 min. at 4°C, and the supernatant (protein lysate) was 
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collected and stored at -80°C.  A Bradford assay was performed to determine protein 
concentration.  
 
 
SDS-Polyacrylamide Gel Electrophoresis (PAGE)/Western Immunoblotting 
 
Protein samples (30-50 µg) were separated (1 h, 100V) on a 10% polyacrylamide 
gel.  Gels were electroblotted onto nitrocellulose membranes (Biorad, Hercules, CA) 
which then were incubated in blocking buffer (1X Tris-buffered saline with 0.1% Tween-
20 (TBS-T), and 5% nonfat dry milk) for 1h at room temperature.  Immunodetection of 
the NFκB p65 subunit was performed overnight at 4°C with anti-phospho p65 and anti-
p65 primary antibodies at 1:250 and 1:400 dilutions, respectively.  After washing, 
membranes were incubated with secondary goat anti-rabbit HRP-conjugated antibody at a 
1:750 dilution for 1 h at room temperature.  Immunodetection of IκBα and phospho-IκBα 
was performed with the respective primary antibodies at 1:400 dilution, and secondary 
goat anti-rabbit HRP-conjugated and goat anti-mouse HRP-conjugated antibodies, 
respectively, at 1:750 dilution.  Immunodetection of the CB2 was carried out with a 
primary anti-human CB2 antibody that was synthesized in rabbits, at a 1:100 dilution.  
The blots were then probed with goat anti-rabbit HRP-conjugated secondary antibody at a 
1:400 dilution.  Detection was carried out with chemiluminescence using ECL reagents 
(Amersham Biosciences, Piscataway, NJ), followed by exposure to X-ray film.  To probe 
for equal protein loading, membranes were stripped with stripping buffer (62.5 mM Tris-
HCl, pH 6.7; 2% SDS;100 mM 2-mercaptoethanol) for 30 min. at 50°C.  Equal loading 
for whole protein lysates and cytoplasmic protein was determined using anti-β actin 
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primary antibody, and equal loading of nuclear protein was determined with anti-PCNA 
(proliferating cell nuclear antigen) primary antibody.     
 
Southern Blot Analysis 
       PCR Synthesis of Digoxigenin-Labeled Probe 
 To confirm the Real-Time RT-PCR results, Southern blot analysis was performed 
on CB1 and CB2 amplicons.  A Digoxigenin (Dig)-labeled probe (Roche, Indianapolis, 
IN) was employed in the Southern analyses instead of the standard radiolabeled probe.  
Digoxigenin (Dig) is a plant steroid hapten that is used in molecular biology techniques 
due to its high immunogenicity.  Dig, like other haptens such as biotin and fluorescein, is 
used as a conjugation tag for the detection of nucleic acids for Southern and Northern 
blot analyses using anti-digoxigenin antibodies.  The Dig-labeled probe was synthesized 
using PCR according to manufacturers instructions.  Synthesis was carried out in a 50 µl 
1X PCR buffer, 200 µM of PCR Dig mix, 100 µg/ml each of downstream and upstream 
gene-specific primers, 5 U of polymerase enzyme, 500 pg of template DNA and sterile 
ddH2O.  The unlabeled control reaction mixture was carried out similarly, except that a 
standard dNTP mix (200 µM) was used instead of the Dig PCR mix.  The probes were 
synthesized in the SmartCycler under the following settings: initial denaturation (95°C, 2 
min.); 30 cycles of denaturation (95°C, 30 sec), annealing (60°C, 30 sec) and elongation 
(72°C, 1 min.); and a final elongation (72°C, 7 min.).  A small aliquot of the PCR 
products was electrophoresed on a 1.5% agarose gel to confirm the presence of the 
unlabeled and Dig-labeled probes for both cannabinoid receptors.  The Dig-labeled CB1 
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was approximately 850 bp in size and the unlabeled probe was of a slightly smaller size 
of 650 bp (Figure 10A).  The Dig-labeling of the CB2 insert generated a 500 bp probe, 
while the unlabeled CB2 probe was about 350 bp in size (Figure10B).  The labeled probe 
was stored at -20°C until used in experiments.     
  
     Hybridization/Detection 
  The agarose gel containing the PCR products was incubated in denaturing 
solution (1.5 M NaCl; 0.5 M NaOH) for 30 min. at room temperature, followed by 
incubation in neutralization solution (1.5 M NaCl;1 M Tris, pH 8) for 30 min.  The gel 
then was incubated in 20X Saline Sodium Citrate (SSC) buffer for 30 min. at room 
temperature.    The transfer apparatus was set up and the PCR products were transferred 
to a nylon membrane overnight at room temperature.  The following day the transferred 
products were UV crosslinked to the nylon membrane using a Stratalinker (Stratagene).  
Hybridization of the crosslinked membrane with a digoxigenin-labeled rat CB1 or mouse 
CB2 probe was carried out according to the manufacturers (Roche) instructions.  The  
membrane was pre-hybridized with hybridization buffer for 30 min. at 42°C, at which 
time the pre-hybridized membrane was incubated with either the CB1 or CB2 
digoxigenin-labeled probe overnight at 40°C.  The Dig-labeled probes were denatured in 
a boiling water bath for 5 min., followed by rapid cooling in an ice water bath.  After the 
overnight hybridization, the membrane was stringently washed 2 times for 5 min. each at 
room temperature in 2X SSC with 0.1% SDS, followed by 2 washes for 15 min. each at 
65°C in 0.5X SSC with 0.1% SDS.  The membrane was briefly washed for 5 min. at 
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room temperature in 1X washing buffer (0.1 M maleic acid; 0.15 M NaCl; pH 7.5; 0.3% 
(v/v) Tween-20), followed by incubation in 100 ml of 1X blocking buffer (10X blocking 
solution diluted 1:10 in 1X maleic acid buffer) for 30 min.  The blocked membrane was 
incubated with anti-digoxigenin antibody (75 mU/ml) for 30 min. at room temperature.  
The membrane underwent a couple of washes in 1X wash buffer as described previously, 
and then was equilibrated in 1X detection buffer (0.1 M Tris-HCl; 0.1 M NaCl; pH 9.5).  
The equilibrated membrane was placed in a plastic report cover, and incubated in 1X 
CPD-Star detection reagent (Roche, Indianapolis, IN) for 5 min. at room temperature.  
CDP-Star is a chemiluminescent substrate that is dephosphorylated by alkaline 
phosphatase, resulting in the formation of a dioxetane phenolate anion.  The 
decomposition of this anion emits a light signal that can be detected on X-ray film.  The 
membranes used in these Southern analyses were exposed to X-ray film (Perkin Elmer, 
Waltham, MA) for detection of CB1 or CB2 PCR products.    
 
Statistical Analysis 
All experiments were performed in triplicate and each experiment was repeated a 
minimum of two times.  To evaluate homogenous data, an analysis of variance 
(ANOVA) was performed using Dunnett's test.  These analyses were followed by a 
Students t-test to compare vehicle control treatment group with the LPS/vehicle control 
group, and to compare LPS/vehicle treatment with drug treatment groups. 
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Results 
 
 
 
EOC-20 Microglial-Like Cells Express the Cannabinoid Receptor CB2 but do not 
Express the Cannabinoid Receptor CB1.   
The CB1 is found predominantly in the brain and has been shown to be expressed 
in astrocytes, oligodendrocytes, neurons and microglia.  While the CB2 is found mainly in 
peripheral immune cells and testis, its expression can also be detected in the brain.  In 
order to assess for cannabinoid receptor expression in EOC-20 microglial-like cells, Real-
Time RT-PCR analysis was performed on total RNA isolated from unstimulated EOC-20 
cells.  The pCD-rSKR6 and pUC18-mCB2 plasmids were restriction-enzyme digested to 
generate DNA inserts (Figure 2) that served as positive controls for CB1 and CB2 Real-
Time RT-PCR assays, respectively.  CB1 mRNA was not detected in EOC-20 cells 
(Figure 3A), but these cells do express low levels of CB2 mRNA (Figure 4A).  The 
threshold cycle (Ct) was set at 30 fluorescence units, and this value is the minimum 
fluorescence level of DNA-bound SYBR green to be detected by a Cephid thermocycler.  
The PCR amplicons for both receptors were resolved by agarose gel electrophoresis, to 
confirm the presence of the 167 bp CB1 amplicon (Figure 3B) and the 207 bp CB2 
amplicon (Figure 4B). These findings are not surprising for mouse EOC-20 microglial-
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     Figure 2. Restriction Enzyme Digestion of pCD-rSKR6 and pUC18- 
        mCB2. (A), The pCD-rSKR6 plasmid containing a DNA insert for  
        the rat CB1 was digested with BamHI and EcoRI to release  
        the 2.4 kb CB1 insert.  A slightly larger DNA fragment (~3 kB) was  
  also generated from the restriction digestion and represents the  
  presence of additional restriction sites for BamHI and/or EcoRI. (B),  
  The pUC18mCB2 plasmid containing a DNA insert for the murine  
  CB2 also was digested with BamHI and EcoRI to release a  
  1.3 kb CB2 fragment.  Fragments from both plasmids were used as  
  controls in Real-Time RT-PCR and Southern blot analyses. 
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Figure 3.  EOC-20 Cells Do Not Express CB1 mRNA. Real-Time RT-PCR with 
SYBR green PCR mix was performed on total RNA isolated from unstimulated 
EOC-20 cells and whole mouse brain homogenate.  A DNA fragment from the 
CB1 plasmid pCD-rSKR6 was used as a positive control. (A), PCR amplification 
of CB1 was detected in mouse brain homogenate (Ct = 34.2) and the positive 
control pCD-rSKR6 (Ct = 14.4).  However, CB1 expression was not detected in 
EOC-20 cells. The crossover threshold (Ct) was set at 30 fluorescence units. (B), 
PCR amplicons were electrophoresed on an agarose gel for confirmation. Lanes: 
1, DNA ladder; 2, negative control; 3, positive control (pCD-rSKR6); 4, EOC-20 
cells; 5, mouse brain homogenate.  The 167 bp CB1 amplicon was only detected 
in the positive control and mouse brain homogenate samples.
EOC- 20; (-)control
Mouse brain; Ct = 34.2
pCD-rSKR6; Ct = 14.4
Ct = 30 
1   2   3   4   5 
     200
100
bp
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         Figure  4. EOC-20 Cells Do Express CB2 mRNA. Real-Time RT-PCR with 
SYBR green PCR mix was performed on total RNA isolated from 
unstimulated EOC-20 cells.  A DNA fragment from the CB2 plasmid pUC18-
mCB2 was used as a positive control. (A), PCR amplification of CB2 mRNA was 
demonstrated in EOC-20 cells (Ct = 30.5) and the positive control pUC18-
mCB2 (Ct = 14.5).  Primers for the housekeeping gene GAPDH was also used as 
a control (Ct = 13.9). The crossover threshold (Ct) was set at 30 fluorescence 
units. (B), PCR amplicons were electrophoresed on an agarose gel for 
confirmation of the 207 bp CB2 amplicon. The smaller PCR product is 
amplification of the GAPDH gene. Lanes: 1, DNA ladder; 2, EOC-20 cells; 4, 
GAPDH; 6, negative control; 7, positive control (pUC18-mCB2). Lanes 3 and 5 
are (-)RT controls for EOC-20 cells and GAPDH, respectively.
(-)control; (-)RT controls 
GAPDH; Ct = 13.87 
EOC-20; Ct = 30.5 
pUC18-mCB2; Ct = 14.5 
Ct = 30 
1    2 3 4 5 6 7 
    300
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 100
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like cells since primary microglia cells have been shown to have low levels of CB1 
expression while being a major contributor of CB2 expression in the brain. 
 
Stimulation of EOC-20 Cells with the Cytokines TNF-α or IFN-γ  Increase p65  
Production. 
To further determine if the EOC-20 cells would be a suitable in vitro model to 
study the effects of cannabinoids on NFκB function in microglia cells, we analyzed  
NFκB activation by way of measuring levels of the p65 subunit upon cell stimulation.  
Induction of the p65 subunit was investigated instead of the p50 subunit because p65  
plays the major role in NFκB activation and function, and it contains the transactivation 
domain responsible for the transcriptional activity of NFκB.  TNF-α is a potent activator 
of microglial cells, thus using an ELISA-based binding assay, we assessed for NFκB 
induction upon stimulation with TNF-α.  Nuclear extract (10 µg), from EOC-20 cells 
stimulated with various concentrations of TNF-α (10 ng/ml  100 ng/ml) for 22 h, was 
added to wells of a 96-well plate pre-coated with a NFκB consensus oligonucleotide 
sequence.  A p65-specific antibody was added to each well, followed by a HRP-
conjugated secondary antibody.  A colorimetric reaction was carried out to obtain a 
quantitative measure of p65 levels for each sample, extrapolated from a standard curve 
using recombinant p65 protein (Figure 5).  Increasing levels of p65 were directly 
proportional to increasing concentrations of TNF-α (Figure 6).  A two-fold increase (0.6 
ng to 1.2 ng) of p65 levels was observed between the lowest TNF-α concentration (10 
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ng/ml) and the highest TNF-α concentration (100 ng/ml) used.  A three-fold and six-fold 
increase of p65 concentration were observed between vehicle (0.2 ng) and 10 ng/ml TNF-
α treated cells, and vehicle and 100 ng/ml TNF-α treated cells, respectively.  For the 
Jurkat cell nuclear extract (2.5 µg) that served as the positive control, 0.8 ng of p65 was 
observed; and there were no measurable levels of p65 in the negative control.  The 
competitor control, consisting of nuclear extract from the 100 ng/ml TNF-α sample 
incubated with 2 pmol of wild-type NFκB consensus oligonucleotide, demonstrated 
levels of p65 comparable to the vehicle (i.e., unstimulated) group.  A seven-fold increase 
of p65 levels was observed between the competitor control and the non-competitor 
control (i.e., the 100 ng/ml TNF-α sample incubated with 2 pmol of a mutated NFκB 
consensus oligonucleotide).  This analysis demonstrates that TNF- α could serve as an 
inducer for NFκB activation in our in vitro cell model. The same approach was used to 
analyze induction of p65 as it relates to NFκB activation in EOC-20 cells upon exposure 
to the cytokine IFN-γ.  IFN-γ can activate macrophages and macrophage-like cells such 
as microglia, and prime them for antigen processing and presentation.  EOC-20 cells 
were treated with 50 U/ml and 100 U/ml IFN-γ for 22 h, and the nuclear extract from 
these treated cells was assessed for NFκB activation.  The TransAM NFκB ELISA 
demonstrated an increase in p65 production in EOC-20 cells upon IFN-γ-induced NFκB 
activation as compared to the vehicle-treated (i.e., unstimulated) cells; however, there 
was only a two-fold increase in p65 production between the stimulated and unstimulated 
cells (Figure 7).  This is a striking difference from the ten-fold increase of p65 production 
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that was observed between vehicle-treated cells and cells stimulated with 100 ng/ml 
TNF-α (Figure 6).  One explanation for the disparity in these results is that TNF-α and 
IFN-γ activate cells through two different signaling pathways.  TNF-α  activates cells 
through the induction of the transcription factor NFκB.  IFN-γ, on the other hand, 
activates cells through the signal transducers and activator of transcription (STAT) family 
of proteins.  Overall levels of p65 production were comparable between the two 
concentrations of IFN-γ.  These results suggest that TNF-α rather than IFN-γ may serve 
as a better inducer of NFκB activity for our in vitro cell model.   
Similar approaches were used to assess LPS-induced NFκB activation in EOC-20 
cells.  LPS is a classical cell activator and inducer of NFκB signaling. Previous studies 
performed in our laboratory as well as others investigated cannabinoid effects on pro-
inflammatory cytokine gene expression in LPS-induced microglial or microglial-like 
cells.  Assessing NFκB binding to its consensus sequence is another manner in which to 
study NFκB induction and any possible effects exerted by cannabinoids. Therefore, using 
Electrophoretic Mobility Shift Assays (EMSA), we assessed LPS-induced NFκB 
induction by way of binding to a synthetic DNA oligonucleotide containing the NFκB 
consensus sequence 5-GGGGATCCC-3.  EOC-20 cells were either vehicle-treated or 
stimulated with 100 ng/ml LPS for 1 h, and the nuclear extracts from these samples were 
assayed.  Conflicting results were obtained from these analyses, for levels of LPS-
induced NFκB binding were comparable to unstimulated cells (Figure 8). FACScan 
analysis was performed on EOC-20 cells in the laboratory of Dr. Kathleen McCoy, and it 
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was determined that these cells have a mutation in the cytoplasmic tail of TLR-4, thus 
causing these cells to be non-responders to LPS.  TLR-4 is the pattern recognition 
receptor that interacts with LPS and leads to activation of NFκB.  We determined that the 
EOC-20 cells may not represent the best cell model for our in vitro studies due to their 
lack of responsiveness to LPS.  In reading through the literature, it was observed that the 
microglial cell line BV-2 had been used widely in studies examining microglial function 
and neuropathology.  Therefore, these cells subsequently were assessed as a model for 
NFκB induction.   
 
Mouse BV-2 Microglial Cells do not Express mRNA for the Cannabinoid Receptor 
CB1.   
 A frozen stock of BV-2 cells was obtained from Dr. Michael McKinley of the 
Mayo Clinic (Jacksonville, FL).  The microglial cell line BV-2 has been used as an in-
vitro model for studying microglial function.  These cells possess functional and 
phenotypic properties common to primary microglia including phagocytic ability, 
secretion of pro-inflammatory cytokines and expression of surface receptors and antigens 
(Blasi et al., 1990).  We initially performed experiments with the BV-2 cells to determine 
if they would be a suitable cell model for our studies. To determine whether BV-2 cells 
can express CB1, we performed Real-Time RT-PCR on RNA isolated from BV-2 cells to 
assess for the presence CB1 mRNA in unstimulated and activated cells.  Complementary 
DNA (cDNA) was synthesized and used in concert with SYBR green PCR mix and 
primers for murine CB1.  BV-2 cells have been shown to become activated by IFN-γ and 
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the bacterial toxin LPS (Blasi et al., 1990; Han et al., 2002; Hwang et al., 2004).  Thus, 
BV-2 cells were seeded overnight in either complete growth medium, IFN-γ (100 U/ml) 
or LPS (1 µg/ml and 10 ng/ml).  CB1 mRNA was neither detected in unstimulated BV-2 
cells nor in stimulated BV-2 cells stimulated with IFN-γ (100 U/ml) and LPS (1 µg/ml or 
10 ng/ml) (Figure 9A).  The pCD-rSKR6 plasmid containing CB1 DNA was used as a 
positive control. 
The 167bp PCR amplicons were resolved on a 4% OmniPure agarose gel (Figure 
9B, top panel) in 1X TBE buffer, and transferred to a nylon membrane in 20X SSC 
buffer.  The transferred DNA was UV crosslinked to the membrane, which was analyzed 
by Southern blot analysis.  An insert from the CB1 plasmid pCD-rSKR6 was isolated and 
labeled with digoxigenin (Figure 10A) to be used as a CB1-specific probe in Southern 
blot analysis to confirm the results of our Real-Time RT-PCR analyses.  Positive 
hybridization was obtained only with the pCD-rSKR6 DNA insert (Figure 9B, bottom 
panel).  All assay controls, including RT-PCR reactions lacking the reverse transcriptase 
enzyme (-RT) and GAPDH controls, were electrophoresed as well. 
 
Mouse BV-2 Microglial Cells Demonstrate A Baseline Level of Expression for 
Cannabinoid Receptor CB2 mRNA. 
The CB2 is localized primarily in peripheral immune cells, but also has been 
identified within the CNS, with microglial cells being the major contributors of CB2 
expression.  We assessed for CB2 mRNA expression using Real-Time RT-PCR analysis 
with SYBR green PCR mix and primers specific for murine CB2.  BV-2 cells were seeded  
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     Figure 5. Standard Curve of Recombinant p65.  TransAM ELISA (Active  
 Motif) using antibodies specific for the p65 subunit demonstrated the  
 detection of serially diluted (10 ng to 0.156 ng) recombinant p65 protein.   
                Such standard curves were used to extrapolate concentrations of the p65       
                protein in experimental samples. Results are presented as ± SEM, n=2. 
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         Figure 6. TNF-α-induced Production of p65 Protein in EOC-20    
          cells. The TransAM NFκB ELISA (Active Motif) demonstrated TNF-    
          α-induced NFκB activation through an increase of p65 production.   
          EOC-20 cells were treated with varying concentrations of TNF-α  
          overnight. The nuclear extracts from these samples were used in  
          ELISA assay. TNF-α exerted a concentration-related increase of p65  
          production in EOC-20 microglial-like upon stimulation with TNF-α.   
          Results are presented as ± SEM, n=2. 
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          Figure 7. IFN-γ-induced Production of p65 Protein in  
          EOC-20 Cells. The TransAM NFκB ELISA (Active Motif)   
          was employed to assay IFN-γ-induced NFκB activation by  
          way of measuring p65 production. EOC-20 cells were  
          treated with 50 U/ml and 100 U/ml of IFN-γ overnight. The  
          nuclear extracts from these samples were used in the  
          ELISA assay. A two-fold increase of p65 concentrations  
          was observed between the IFN-γ treated cells and the  
          vehicle treated cells.  Both concentrations of IFN-γ gave  
          comparable levels of p65 concentration in the EOC-20  
          cells.  The level of p65 in the negative (-) control was  
          undetectable in this assay.  Result presented as ± SEM, n=2. 
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Figure 8.  NFκB Binding is Exhibited in Unstimulated and LPS-  
stimulated EOC-20 Cells.  EOC-20 cells were treated for 1 h with complete    
DMEM, 100 ng/ml LPS, and 100 ng/ml LPS with vehicle (0.01% ethanol).   
               The nuclear extracts from these treatment groups were assessed for  
               NFκB binding to a synthetic radiolabeled DNA oligonucleotide probe.    
               Comparable levels of NFκB binding were observed in all treatment  
               groups.  Lanes: 1, unstimulated; 2, LPS alone; 3, LPS and vehicle. 
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overnight in either complete growth medium, IFN-γ (100 U/ml), or LPS (1 µg/ml and 10 
ng/ml).  As described previously, a DNA insert from the CB2 plasmid pUC18-mCB2  
served as the positive control and a PCR reaction mixture lacking cDNA served  as the 
negative control (Figure 11A). CB2 mRNA expression was observed in unstimulated BV-
2 cells, indicating that these cells have a baseline level of CB2 mRNA expression (Figure 
11B).  Primary microglia cells in vitro have demonstrated differential gene expression of 
the CB2 during their various activation states (Carlisle et al., 2002).  microglial cells have 
an increased level of CB2 gene expression during primed and responsive states of 
activation, and a lower level of gene expression once these cells are fully activated. Based 
on the fluorescence levels of the different treatment groups, we observed an augmented 
level of CB2 mRNA expression, when compared to the baseline level, in BV-2 cells 
treated with 100 U/ml IFN-γ, which drives microglial cells into a responsive state of 
activation (Figure 11B).  The lowest levels of fluorescence were observed in cells treated 
with 1 µg/ml LPS and 10 ng/ml LPS, which can fully activate microglia cells.  Gel 
electrophoresis of the RT-PCR amplicons also reflects the differential expression of CB2 
mRNA among the different cell treatments (Figure 12A, top panel).  Southern blot 
analysis was performed to confirm the Real-Time RT-PCR results using a digoxigenin-
labeled probe generated from the pUC18-mCB2 plasmid (Figure 10B).  Positive CB2 
hybridization was observed for all treatment groups (Figure 12A, bottom panel).  Western 
blot analysis was carried out to assess expression of CB2 at the protein level in untreated 
and stimulated BV-2 cells.  A human anti-CB2 antibody synthesized in rabbits (Nowell 
KW, 1998) was used to detect CB2 protein expression in all treatment groups (Figure  
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Figure 9. BV-2 Microglial-like Cells Do Not Express CB1.  BV-2 cells were 
stimulated overnight with complete DMEM, 100 U/ml IFN-γ, 1 µg/ml LPS or 10 
ng/ml LPS.  (A), Real-Time RT-PCR analysis was performed on total RNA isolated 
each group using CB1 specific primers and SYBR green PCR mix. CB1 mRNA was 
not detected in untreated or stimulated BV-2 cells. The CB1 plasmid pCD-rSKR6 
(Ct=14.6) served as the positive control. (B), Top panel, PCR reactions were resolved 
by agarose gel electrophoresis. Bottom panel, Southern blot analysis using a 
digoxigenin-labeled mouse CB1 specific probe.  Hybridization was obtained only for 
the CB1-positive control (arrow). Lanes: 1, DNA ladder, 2, negative control; 3, 
positive control (pCD-rSKR6 plasmid); 4, untreated; 6, 100 U/ml IFN-γ; 8, 1 µg/ml 
LPS; 10, 10  ng/ml LPS; Lanes 5, 7, 9 and 11, (-)RT controls, respectively. The 
crossover threshold (Ct) was set at 30 fluorescence units.
pCD-rSKR6; Ct = 14.6 
(-)control, (-)RT controls; 
untreated; 100 U/ml IFN-γ; 
1 µg/ml LPS; 10 ng/ml LPS
Ct = 30
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Figure 10. PCR Synthesis of Digoxigenin-Labeled CB1 and CB2 Probes.  
DNA inserts from pCD-rSKR6 (CB1) and pUC18-mCB2 (CB2) plasmids 
were PCR labeled with digoxigenin and used as specific probes for 
Southern blot analyses.  The Dig labeling resulted in slightly larger 
amplicons than the unlabeled amplicons. (A), The Dig-labeled CB1 and 
unlabeled CB1 probes were approximately 850 bp and 650 bp in size, 
respectively. (B), Dig-labeled CB2 and unlabeled CB2 probes were 
approximately 500 bp and 350 bp in size, respectively. Lanes: 1, DNA 
ladder; 2, Dig-labeled probes; 3, unlabeled probes.   
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Figure 11. Untreated and Stimulated BV-2 Microglial-like Cells Express CB2.  BV-2 
cells were stimulated overnight with complete DMEM, 100 U/ml IFN-γ, 1 µg/ml LPS 
or 10 ng/ml LPS.  (A), The graphs depict the negative control and amplification of 
DNA from the CB2 plasmid pUC18-mCB2 (Ct = 14.7), which served as the positive 
control (B), Real-Time RT-PCR analysis was performed on total RNA isolated from 
each group using CB2 specific primers and SYBR green PCR mix. CB2 mRNA was 
detected in untreated cells (Ct = 27.5), 100 U/ml IFN-γ treated cells (Ct = 27.0), and 
cells stimulated with 1 µg/ml LPS (Ct = 30.1) and 10 ng/ml LPS (Ct = 27.7). There 
was no amplification detected in the (-)RT controls. The crossover threshold (Ct) 
was set at 30 fluorescence units. 
(-) control 
pUC18-mCB2; Ct = 14.7 
Ct = 30 
(-)RT controls 
1 µg/ml LPS; Ct = 30.1 
10 ng/ml LPS; Ct = 27.7 
untreated; Ct = 27.0 
100 U/ml IFN-γ; Ct = 27.5 
Ct = 30 
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Figure 12. CB2 Epression in BV-2 Cells.  Agarose gel electrophoresis and Southern 
blot analysis were performed on Real-Time RT-PCR reactions to confirm the 
presence of the 204 bp CB2 amplicon. (A), Top panel, Gel electrophoresis of RT-PCR 
amplicons resolved on a 4% agarose gel. CB2 expression was observed in the 
positive control, untreated cells and cells stimulated with IFN-γ or LPS. Bottom 
panel, Southern blot analysis using a digoxigenin-labeled CB2 specific probe.  
Positve hybridization was obtained for all samples. Lanes: 1, DNA ladder; 2, 
negative control; 3, positive control (pUC18-CB2 plasmid); 4, untreated; 6, 100 U/ml 
IFN-γ; 8, 1 µg/ml LPS; 10, 10 ng/ml LPS. Lanes 5, 7, 9, and 11 are (-) RT controls, 
respectively. (B), Top panel, Western blot analysis of mouse CB2; Lanes: 1, 
untreated; 2, 100 U/ml IFN-γ; 3, 1 µg/ml LPS; 4, 10 ng/ml LPS. Bottom panel, Equal 
protein loading control.  The blot was stripped and reprobed with anti-β-actin 
antibody. 
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12B, top panel).  Equal protein loading was assessed using a beta-actin antibody (Figure 
12B, bottom panel). 
 
 
LPS Induces NFκB Binding in BV-2 Microglial Cells.   
 
 The major objective for this study is to assess cannabinoid effects on NFκB 
activity and regulation upon LPS-induced cell activation.  In vitro, full activation of 
microglia can be replicated using LPS, resulting in an induction of pro-inflammatory 
cytokine genes that are NFκB-regulated.  Activation of the NFκB signaling cascade 
results in several downstream signaling events that culminate in the translocation of 
NFκB into the nucleus, binding to its gene promoter recognition site and gene 
transcription.  Initially, we assessed for LPS-induced NFκB binding of BV-2 cells using 
electrophoretic mobility shift assays (EMSA).  BV-2 cells were left untreated in complete 
growth medium or stimulated with 100 ng/ml LPS for various time intervals (5 min., 10 
min., 15 min., 30 min., 60 min.) to determine the optimal time kinetics for NFκB binding 
to a synthetic oligonucleotide probe.  The synthetic probe is representative of the NFκB 
cognate consensus sequence in vivo.  The 100 ng/ml concentration of LPS was used 
based on published reports that demonstrated this concentration could robustly activate 
and elicit an immune response from BV-2 cells (Kim et al., 2005; Kremlev et al., 2004).  
To perform the EMSAs, binding reactions were made using 4 µg of nuclear protein 
extracted from each sample group and 1-2 µl of a 32P-labeled probe with a Cerenkov 
count of >1x105cpm/µl.  The DNA-protein complexes or shifts observed demonstrated 
LPS-induced NFκB binding as early as 10 min. and as late as 60 min. (Figure 13).  There 
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was no binding observed in the untreated sample.  Based on these results, it was 
determined that LPS stimulation for 30min. would be an optimum time to stimulate cells 
with LPS and investigate any possible cannabinoid-mediated modulation of LPS-induced 
NFκB binding.   
 The concentration of nuclear protein (4 µg) used in these assays was determined 
in a protein titration assay using several concentrations of nuclear protein (1  8 µg) 
extracted from LPS-stimulated BV-2 cells (Figure 14, left panel) and LPS-stimulated 
primary microglial cells (Figure 14, right panel).   Based on the DNA-protein complexes 
formed in this experiment, it was determined that 4 µg of nuclear protein would be 
optimal for our binding assays.   
 To confirm specificity of the oligonucleotide probe used in the mobility shift 
assays, we performed cold competition and non-competition experiments using a two-
fold increase of a wild-type NFκB probe which served as the competitor, and a two-fold 
increase of a mutated NFκB probe which served as the non-competitor.  The excess of 
unlabeled wild-type probe competed with and prevented interaction of the 32P-labeled 
probe with the nuclear extract, thus preventing formation of the DNA-protein complex 
(Figure 15A, left lane).  A mutation in the recognition sequence of the mutated unlabeled 
probe does not prevent proper recognition and binding by NFκB, thus allowing the 32P-
labeled probe to bind to the nuclear protein as expected (Figure 15A, right lane).  In 
addition, supershift assays were performed using antibodies against the p65 and p50 
subunits of the NFκB heterodimer.  The protein-DNA complexes formed larger  
 59
 
 
                     
                     Figure 13.  Time Kinetics of LPS-Induced NFκB Binding in BV-2  
                    Cells. BV-2 cells were either untreated (-) or stimulated with  
                    100 ng/ml of LPS for the indicated time intervals (5 min.  60 min.).   
                    Nuclear protein was extracted from all treatment groups and  
                    assayed by electrophoretic mobility shift assay (EMSA) using a  
                    32P-labeled, NFκB oligonucleotide probe. Based on the time  
                    kinetics of LPS-induced NFκB binding in BV-2 cells, it was  
                    determined that the 30 min. time interval would be an optimal  
                    time to assess binding. The untreated cells did not demonstrate  
                    binding to the synthetic, radiolabeled probe as expected.                          
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 Figure 14.  Nuclear Protein Titration of BV-2 Cells and Primary Microglia.   
 BV-2 cells and primary microglia (1° Mg) cells were stimulated with  
 100 ng/ml LPS (30 min.).  Varying concentrations (1 µg  8 µg) of nuclear  
 protein extracted from the stimulated cells were assessed for binding to a  
 synthetic NFκB probe to determine the optimal protein concentration for  
 the EMSAs. The results observed with both cell types indicate that 4 µg of  
 nuclear protein was sufficient to form the protein-DNA complexes or  
 shifts. 
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            Figure 15. The Specificity of the Radiolabeled Probe Employed in the    
            Mobility Shift Assays. (A), Cold competitor and non-competitor assays were  
            performed on nuclear protein extracted from LPS-stimulated BV-2 cells.   
            For the cold competitor analysis, a 2-fold increase of an unlabeled NFκB  
            probe was incubated with the nuclear protein and the 32P-labeled NFκB  
            probe.  The unlabeled probe prevented protein-DNA complex or shift  
            formation (Lane 1).  For the cold non-competitor analysis, the unlabeled  
            mutant probe will not be recognized by NFκB, thus allowing shift formation  
            of NFκB and the 32P-labeled probe (Lane 2). (B), Supershift assays using  
            antibodies against the p65 and the p50 subunits of NFκB were performed.   
            The p65 antibody (Lane 1) and the p50 antibody (Lane 2) formed larger  
            complexes or super-shifts through interaction with the NFκB-32P-labeled  
probe shifts.  
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complexes or supershifts with the anti-p65 (Figure 15B, left lane) or anti-p50 antibody 
(Figure 15B, right lane). 
 
The Partial Cannabinoid Receptor Agonist ∆9-THC Exerts an Inhibitory Effect on 
NFκB Binding in LPS-Stimulated BV-2 Cells. 
Cannabinoids such as ∆9-THC have been shown to down-regulate the gene 
expression of pro-inflammatory cytokines (Puffenbarger et al., 2000; Curran et al., 2005), 
however such modulation is not due to message degradation (Fischer-Stenger et al., 1993; 
Puffenbarger et al., 2000).  Thus, we examined if the partial cannabinoid receptor agonist 
∆9-THC affects pro-inflammatory cytokine gene expression at the promoter and/or 
transcriptional level by altering the ability of NFκB to bind to its cognate promoter 
binding sequence. BV-2 cells were pre-incubated with ∆9-THC (3 h) and then stimuated 
with 100 ng/ml LPS for 30 min.  Nuclear extracts were used to analyze the induction of 
NFκB binding to the synthetic DNA probe.  EMSA analyses demonstrated that ∆9-THC 
inhibited NFκB binding in LPS treated BV-2 cells in a concentration-related fashion.  As 
concentrations approached the nanomolar level, inhibition of NFκB binding was 
increased as compared to the higher concentrations, with significant inhibition occurring 
at the 10-7M and 10-8M concentrations, and maximal inhibition occurring at the 10-8M 
concentration (Figure 16A).  This bimodal effect, typical of lipophilic cannabinoid 
compounds, is exemplified by the initial inhibition and subsequent dissipation of the 
inhibitory effect at the 10-5M and 10-6M concentrations, respectively.  As decreasing 
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concentrations of ∆9-THC approach the nanomolar level, inhibition of NFκB binding is 
observed once again.  The 10-5M concentration of ∆9-THC is an extremely high 
concentration of this lipophilic compound, and effects observed at this concentration may 
reflect non-specific action through membrane activation and/or perturbation.  High levels 
of ∆9-THC also have been shown to cause apoptosis in microglial-like cells, suggesting 
that the lack of NFκB binding at 10-5M may be due to a decreased number of viable cells.  
Responses observed approaching or at nanomolar levels are consistent with receptor-
mediated effects.  Densitometric measurements of the protein-DNA complexes were 
taken and percent binding of the treatment groups was calculated as compared to the LPS 
treatment group that served as the positive control (Figure 16B).  
 
The Full Cannabinoid Receptor Agonist CP55940 Exerts an Inhibitory Effect on LPS-
Induced NFκB Binding in BV-2 Cells. 
The synthetic agonist CP55940 also has been shown to inhibit gene expression of 
pro-inflammatory cytokines (Puffenbarger et al., 2000).  Similarly to ∆9-THC, we 
assessed the effects of CP55940 on NFκB binding in LPS-stimulated BV-2 cells.  
CP55940 inhibited the binding activity of NFκB in a concentration-related fashion 
comparable to that observed with ∆9-THC (Figure 17A).  Significant inhibition of NFκB 
binding ranged from 10-7M to 10-9M concentrations of CP55940.  The maximal 
inhibitory effect of CP55940 on NFκB binding was observed at 10-9M concentration, 
distinct from the maximal inhibitory effect of ∆9-THC at the 10-8M concentration.  These 
results were not unexpected, for CP55940 acts as a full agonist to both cannabinoid 
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receptors and therefore would have greater efficacy than the partial agonist ∆9-THC upon 
receptor interaction.  As observed with ∆9-THC, inhibition of NFκB binding was 
observed at the 10-5M concentration of CP55940, which dissipated at the 10-6M 
concentration, once again demonstrating the biphasic effects of cannabinoid compounds.  
Densitometric measurements of the protein-DNA complexes were taken and percent 
binding of the treatment groups was calculated as compared to the LPS treatment group 
that served as the positive control (Figure 17B).  
 
Time Dependent NFκB Transcriptional Activity in LPS-Stimulated BV-2 Cells. 
We have demonstrated that both ∆9-THC and CP55940 inhibit the binding of 
NFκB to a synthetic oligonucleotide probe that contains its cognate consensus sequence.  
We next determined a functional linkage of cannabinoid-mediated inhibition of 
consensus sequence binding to NFκB transcriptional activity.  Using a luciferase-based 
reporter activity assay, we investigated the ability of NFκB to induce the transcription of 
the luciferase gene (Luc) upon LPS stimulation.  BV-2 cells were transiently transfected 
with the pNFκB-Luc reporter plasmid that contains the Luc gene, which is driven by a 
basic TATA box promoter element (Figures 18 and 19).  Directly upstream from the 
TATA box is an inducible NFκB enhancer element that contains 5 copies of the NFκB 
consensus sequence.  Upon binding of NFκB to this enhancer element, the Luc gene is 
transcribed and ultimately results in the production of the luciferase protein.  The level of 
luciferase measured is directly proportional to NFκB transcriptional activity.  We initially  
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          Figure 16.  The Partial Cannabinoid Receptor Agonist ∆9-THC  
          Inhibits LPS-induced NFκB Binding in BV-2 cells.  BV-2 cells were pre- 
          treated (3 h) with vehicle (0.01% ethanol) or ∆9-THC at the indicated  
          concentrations.  Binding of nuclear extracts to the 32P-labeled,  
          oligonucleotide NFκB probe then was analyzed by EMSA.  ∆9-THC    
          inhibited NFκB binding in a concentration-related fashion. (A),  
          A representative autoradiogram of NFκB EMSA analysis.  (B),  
          Densitometric representation depicting percent binding as compared to  
          the LPS/vehicle positive control treatment group.  Densitometric  
          measurement of the vehicle treatment was substracted as the       
          background from each group. Results are presented as the mean ± SD,  
    *p<0.001; **p<0.01; ***p<0.05.
               ∆9-THC (log10M)   0      0      -5       -5      -6      -7      -8      -9     -10    
100ng/mL LPS 
LP
S/
ve
h
-5M
 
-5M
 
-6M
 
-7M
 
-8M -9M -10
M 
0
50
100
150
log10 ∆9-THC
LPS
*
** **
***
%
 B
in
di
ng
 66
 
A. 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  The Full Cannabinoid Receptor Agonist CP55940 Inhibits 
LPS-induced NFκB Binding in BV-2 Cells.  BV-2 cells were pre-treated (3 
h) with vehicle (0.01% ethanol) or CP55940 at the indicated 
concentrations.  Binding of nuclear extracts to the 32P-labeled, 
oligonucleotide NFκB probe then was analyzed by EMSA.  CP55940 
inhibited NFκB binding in a concentration-related fashion. (A), A 
representative autoradiogram of NFκB EMSA analysis.  (B), 
Densitometric representation depicting percent binding as compared to 
the LPS/vehicle positive control treatment group.  Densitometric 
measurement of the vehicle treatment was substracted as the background 
from each group. Results are presented as the mean ± SD, *p<0.01; 
**p<0.05. 
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assessed the time kinetics of LPS-induced NFκB transcriptional activity as it relates to 
the production of luciferase.  Actual protein synthesis occurs further downstream from 
receptor-ligand interaction, cell activation, and signaling events that lead to gene 
transcription.  BV-2 cells transfected with the pNFκB-Luc plasmid were either treated  
with vehicle (0.01% ethanol) or 100 ng/ml LPS for various time periods (1 h, 3 h, 8 h and 
overnight).  The amount of luciferase produced from each treatment sample was 
measured, and from this analysis it was determined that LPS stimulation for 3 h provided 
distinguishable measurements of luciferase protein when compared to vehicle treated 
samples of that same time point (Figure 20).   
 
The Exogenous Cannabinoids ∆9-THC and CP55940 Exert Inhibitory Effects on the 
Transcriptional Activity of NFκB in LPS-Stimulated BV-2 Cells. 
To assess the effects of cannabinoids on LPS-induced NFκB transcriptional 
activity, BV-2 cells transfected with the pNFκB-Luc reporter plasmid were treated (3 h) 
with varying concentrations of the partial cannabinoid agonist ∆9-THC or the full agonist 
CP55940 prior to stimulation with LPS (3 h).  These cells were co-transfected with the 
control reporter plasmid pSV-β-gal (Figures 21 and 22).  The pSV-β-gal plasmid has 
constitutive expression of the β-gal gene, therefore levels of the β-galactosidase enzyme 
can be measured to determine transfection efficiency and/or normalization.  After drug 
treatment and LPS stimulation, cells were lysed and luciferase and β-galactosidase levels 
were measured using a luminometer.  ∆9-THC exerted a concentration-related inhibition 
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of NFκB transcriptional activity, with a significant decrease in the transcription of the 
Luc gene occurring from the 10-7M to the 10-9M concentrations (Figure 23).  The greatest 
inhibitory effect on transcriptional activity occurred at 10-8M concentration of ∆9-THC, 
which is the same concentration of ∆9-THC that exhibited maximum inhibition of NFκB 
binding demonstrated in the EMSA analyses (Figure 16).  These observations suggest 
that there is a functional linkage between the diminished ability of NFκB to bind to its 
cognate promoter site and its ability to mediate gene expression.  Similar effects were 
observed with CP55940.  The greatest CP55940-mediated inhibition of transcriptional 
activity occurred at the 10-9M concentration (Figure 24), but significant down-regulation 
of NFκB transcriptional activity also was observed at the 10-7M and 10-8M 
concentrations.   In both the ∆9-THC and CP55940 assays, minimal levels of the 
luciferase reporter were detected in the vehicle and cannabinoid treated cells lacking LPS 
stimulation.  As with the EMSA analyses, the 10-6M and 10-10M concentrations of either 
cannabinoid did not have inhibitory effects on transcriptional activity and were similar to 
the level of activity observed with the LPS control treatment group.  As demonstrated 
previously with the binding studies, the results from the reporter activity assays 
demonstrate the biphasic manner in which cannabinoids are exerting their effects on 
NFκB activity.  The effects of ∆9-THC and CP55940 on NFκB binding and 
transcriptional as concentrations approach the nanomolar level suggest that their effects 
are receptor-mediated. 
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Figure 18. The pNFκB-Luc Reporter Plasmid (Stratagene).  The 5.7 kb plasmid has 
an ampicillin resistance ORF (bla), which confers resistance to transformed 
bacterial cells, and a pUC origin of replication.  The reporter gene Luc is driven by 
a basic TATA box promoter element and the NFκB enhancer.  The enhancer 
contains 5 repeats of the consensus sequence 5-TGGGGACTTTCCGC-3. 
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                   Figure 19. EcoRV Digestion of pNFκB-Luc. The reporter plasmid  
                   pNFκB-Luc was digested with EcoRV restriction enzyme. Gel  
                   electrophoresis of purified plasmid samples were of the same  
                   size as the 5.7 kb stock pNFκB-Luc plasmid. Lanes: 1, DNA ladder;       
                   2, EcoRV digestion of purified pNFκB-Luc (Sample A); 3, EcoRV  
                   digestion of purified pNFκB-Luc (Sample B); 4, EcoRV  
                   digestion of stock pNFκB-Luc plasmid (Stratagene); 5,  
                   undigested stock pNFκB-Luc plasmid.     
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                   Figure 20. Time Kinetics of NFκB-Induced Luciferase Production in LPS  
                   Stimulated BV-2 Cells. BV2 cells were transfected with pNFκB-Luc  
                   reporter plasmid in complete growth medium.  Time kinetics of LPS- 
                   induced NFκB transcriptional activity was determined (24 h post  
                   transfection) by stimulating cells with 100 ng/mL LPS for the indicated  
                   time intervals.  The (3 h) time interval was chosen for all subsequent   
                   drug experiments because of the significant distinguishable increase of  
                   luciferase levels as compared to the vehicle treatment at 3 h.  *P <0.001;  
                   **P = 0.014.   
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   Figure 21. The pSV-β-gal Control Plasmid (Promega).  This 6.8 kb plasmid 
also confers ampicillin resistance (Ampr) to transformed bacterial cells, and 
also has the lacZ gene, the coding sequence for the beta-galactosidase 
enzyme. In addition to multiple restriction sites, pSV-β-gal has a SV40 
promoter and enhancer site, and E. coli cells transformed with this plasmid 
will display constitutive expresion of lacZ due to the E. coli gpt promoter 
(coding region 428-433).             
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                        Figure 22. EcoRI Digestion of pSV-βgal and EcoRV  
                        Digestion of pNFκB-Luc.  The restriction enzyme digestions  
                        of both pSV-βgal and pNFκB-Luc were performed at the  
                        Molecular Biology Core Facility at VCU.  Lanes: 1, DNA ladder;  
                        2, plasmid prep sample of the undigested pSV-βgal plasmid; 3, EcoRI  
                        digestion of pSV-βgal that generated a 6.8 kb DNA fragment,  
                        which is the size of the plasmid, as well as two smaller  
                        fragments that are approximately 4 kb and 3.5 kb in size; 4,  
                        plasmid sample of the undigested pNFκB-Luc plasmid; 5,  
                        EcoRV digestion of pNFκB-Luc that generated a 5.7 kb DNA  
                        fragment, the size of the pNFκB-Luc plasmid; 6, DNA ladder.   
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Figure 23. ∆9-THC Down-Regulates the Transcriptional Activity of NFκB in BV-2 
Cells. At 24 h post transfection, BV-2 cells were treated (3 h) with vehicle (0.01% 
ethanol) and ∆9-THC at the indicated concentrations, followed by stimulation (3 h) 
with 100 ng/mL LPS. After LPS treatment, cells were collected, luciferase was 
extracted from lysed cells and measured.  Background luciferase levels were 
substracted from each sample and normalized to β-galalctosidase levels.  Percent 
activity of all treatment groups was determined. ∆9-THC inhibited the transcription 
of the NFκB-regulated luciferase gene (Luc) in a concentration-related manner.  The 
greatest inhibitory effect was observed at the 10-8M concentration.  The assays were 
repeated three times in triplicate.  The results are presented as the mean ± SD. 
*p<0.01, **p<0.001, ***p<0.05. 
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Figure 24. CP55940 also Down-Regulates the Transcriptional Activity of NFκB in 
BV-2 Cells. At 24 h post transfection, BV-2 cells were treated (3 h) with vehicle 
(0.01% ethanol) and CP55940 at the indicated concentrations, followed by 
stimulation (3 h) with 100 ng/mL LPS. After LPS treatment, cells were collected, 
luciferase was extracted from lysed cells and measured.  Background luciferase 
levels were substracted from each sample and normalized to β-galalctosidase levels.  
Percent activity of all treatment groups was determined. CP55940 inhibited the 
transcription of the NFκB-regulated luciferase gene (Luc) in a concentration-related 
manner.  The greatest inhibitory effect was observed at the 10-9M concentration.  
The assays were repeated three times in triplicate.  The results are presented as the 
mean ± SD. *p<0.01, **p<0.05. 
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The Inhibitory Effects on NFκB Binding and Transcriptional Activity are not 
Mediated through CB1. 
 Both the EMSA analyses and the NFκB reporter activity assays demonstrate that 
both ∆9-THC and CP55940 down-regulate binding and transcriptional activity of NFκB 
in LPS-stimulated BV-2 cells.  We investigated the specificity in which both exogenous  
cannabinoids are exerting inhibitory effects by determining if the effects are mediated 
through CB1, CB2 or in a non-CB1/non-CB2 mode.  Through Real-Time RT-PCR 
analysis, BV-2 cells were shown to express CB2 mRNA but not CB1 mRNA (Figures 9 
and 11).  Although BV-2 cells did not exhibit detectable levels of CB1, we performed 
reporter activity assays on BV-2 cells treated with the CB1 selective agonist ACEA and 
the CB1 selective antagonist SR141716A.  Inhibitory effects and the blocking of such 
inhibitory effects exerted by ACEA and SR141716A, respectively, could possibly give 
insight as to whether another cannabinoid receptor is involved.  BV-2 cells were pre-
treated with decreasing concentrations of ACEA (3 h) 24 h-post transfection, followed by 
stimulation with 100 ng/ml for 3 h.   The level of transcriptional activity of ACEA-treated 
samples were comparable to that of the LPS treated positive control group (Figure 25); 
thus, ACEA did not exert an inhibitory effect on NFκB transcriptional activity.  We 
complemented these studies with competition assays using the CB1 antagonist 
SR141716A in concert with the full agonist CP55940.  Twenty-four hours post 
transfection, BV-2 cells were treated with SR141716A (10-6M) for 1 h, and with 
CP55940 (10-7M) for 3 h prior to stimuation with LPS.  The 10-7M concentration of 
CP55940 was used because a significant decrease of transcriptional activity was 
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consistently observed at this concentration.  BV-2 cells treated with vehicle and 
LPS/vehicle served as the negative and positive controls, respectively.  LPS-stimulated 
BV-2 cells pre-treated with CP55940 without prior exposure to the antagonist 
SR141716A was used as the comparative group for assessing the effects of SR141716A.  
The exposure to SR141716A prior to cannabinoid treatment did not block the inhibitory 
effect of CP55940 (Figure 26); thus, comparable levels of activity were observed 
between SR141716A and CP55940 treated, stimulated BV-2 cells and CP55940 treated, 
stimulated cells. The results from these studies demonstrate that ∆9-THC and CP55940 
exert effects in a CB1-independent manner. 
 
The Cannabinoid-Mediated Inhibitory Effects on NFκB Binding and Transcriptional 
Activity are Mediated, In Part, Through CB2. 
We have demonstrated through receptor specificity studies that the inhibitory 
effects exerted by ∆9-THC and CP55940 are not mediated through CB1.  Those findings 
were expected, for Real-Time RT-PCR analysis revealed that BV-2 microglial cells do 
not express mRNA for CB1.  We then performed receptor specificity studies to determine 
if the effects of ∆9-THC and CP55940 are exerted by CB2.  As described previously with 
the CB1 specificity studies, transfected BV-2 cells were pre-treated (3 h) with the CB2-
selective ligand O-2137 or the CB2-selective antagonist SR144528 in concert with 
CP55940.   There was a significant decrease in transcriptional activity observed in the O-
0137 treated cells ranging from the 10-7M to 10-10M concentrations, with the 10-8M 
concentration exhibiting the maximum down-regulation (Figure 27).  It was observed that 
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the level of inhibition of NFκB transcriptional activity was not as profound with O-2137 
as was observed with ∆9-THC and CP55940.  The selectivity of O-2137 is based on its 
affinity to bind to CB2 and not its responsiveness upon interaction with the receptor, and 
therefore O-2137 may not be as efficacious as ∆9-THC and CP55490. To further 
investigate the involvement of CB2, we exposed BV-2 cells to the CB2-selective 
antagonist SR144528 (10-6M) for one hour prior to CP55940 (10-7M) treatment and LPS 
stimulation.  As described previously, treatment with CP55940 resulted in a significant 
decrease in transcriptional activity as compared to LPS treated cells; however, treatment 
with SR144528 prior to incubation with CP55940 blocked the inhibitory effect of 
CP55940 (Figure 28). The level of transcriptional activity observed in SR144528-treated 
cells was not returned to the level of activity observed with LPS-stimulated cells, but 
there was a significant increase of transcriptional activity when compared to CP55940-
treated cells that were not exposed to SR144528. The combined results of the CB1 and 
CB2 specificity studies suggest that ∆9-THC and CP55940 are exerting inhibitory effects 
on NFκB binding and activity through interaction with the CB2.   
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Figure 25. The CB1-Selective Agonist ACEA Does Not Inhibit the 
Transcriptional Activity of NFκB in BV-2 Cells. At 24 h post 
transfection, BV-2 cells were treated (3 h) with vehicle (0.01% ethanol) 
and ACEA at the indicated concentrations, followed by stimulation (3 
h) with 100 ng/mL LPS. After LPS treatment, cells were collected, 
luciferase was extracted from lysed cells and measured.  Background 
luciferase levels were substracted from each sample and normalized to 
β-galalctosidase levels.  Percent activity of all treatment groups was 
determined. Comparable levels of transcriptional activity were 
observed between the ACEA-treated, LPS-stimulated BV-2 cells and 
LPS-stimulated BV-2 cells. All assays were performed twice in 
triplicate. The results are presented as the mean ± SD. *p<0.01, 
**p<0.05. 
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Figure 26. The CB1-Selective Antagonist SR141716A (SR1) Does Not Block 
the Inhibitory Effects of CP55940 on NFκB Transcriptional Activity. NFκB 
reporter activity assays were performed on LPS-stimulated BV-2 cells pre-
treated separately with the CB1 antagonist SR141716A at 10-6M (1 h) and 
CP55940 at 10-7M (3 h). After LPS treatment, cells were collected, luciferase 
was extracted from lysed cells and measured.  Background luciferase levels 
were substracted from each sample and normalized to β-galalctosidase levels.  
Percent activity of all treatment groups was determined. CP55940 exhibited 
an inhibitory effect on transcriptional activity but that effect was blocked by 
SR141716A.  The results are presented as the mean ± SD, *p<0.01, **p<0.05. 
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Figure 27. The CB2-Selective Ligand O-2137 Partially Inhibits the 
Transcriptional Activity of NFκB in BV-2 Cells. At 24 h post 
transfection, BV-2 cells were treated (3 h) with vehicle (0.01% ethanol) 
and O-2137 at the indicated concentrations, followed by stimulation (3 
h) with 100 ng/mL LPS. After LPS treatment, cells were collected, 
luciferase was extracted from lysed cells and measured.  Background 
luciferase levels were substracted from each sample and normalized to 
β-galalctosidase levels.  Percent activity of all treatment groups was 
determined. Although on a smaller scale, O-2137 significantly inhibited 
the transcriptional activity of NFκB, with maximum inhibition 
occurring at the 10-8M concentration. All assays were performed twice 
in triplicate. The results are presented as the mean ± SD. *p<0.001, 
**p<0.05. 
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   Figure 28. The CB2-Selective Antagonist SR144528 (SR2) Blocks the 
CP55940-Mediated Inhibition of NFκB Transcriptional Activity. NFκB 
reporter activity assays were performed on LPS-stimulated BV-2 cells pre-
treated separately with the CB2 antagonist SR144528 at 10-6M (1 h) and 
CP55940 at 10-7M (3 h). After LPS treatment, cells were collected, 
luciferase was extracted from lysed cells and measured.  Background 
luciferase levels were substracted from each sample and normalized to β-
galalctosidase levels.  Percent activity of all treatment groups was 
determined. CP55940 exhibited an inhibitory effect on transcriptional 
activity, and that inhibition was blocked by SR144528. The results are 
presented as the mean ± SD, n=4. *p<0.01, for treatment groups compared 
with the LPS/vehicle control treatment. ψp<0.01, for CP55940-treated cells 
compared to CP55940-treated cells exposed to SR2. #p<0.05, for SR2 alone 
treated cells compared to CP55940-treated cells exposed to SR2. 
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The Non-CB1/Non-CB2 Selective Agonist O-2095 does not Exert Inhibitory Effects on 
NFκB Transcriptional Activity. 
 The results of our studies thus far suggest that ∆9-THC and CP55940 are exerting 
effects at least in part through the CB2.  We investigated whether another cannabinoid 
subtype could also mediate the effects observed with ∆9-THC and CP55940.   
The synthetic cannabinoid agonist O-2095 does not exhibit selectivity to either CB1 or 
CB2 but elicits a pharmacological response (Ng et al., 1999).  O-2095 does demonstrate 
selectivity to vanilloid receptors, and it has been suggested that the vanilloid receptor 
TRVP-1 functions as a cannabinoid receptor (Smart et al., 2000; Ross, 2003).  Any O-
2095-mediated effects on the activity of NFκB may suggest the involvement of another 
cannabinoid receptor subtype.  To determine if cannabinoid-mediated inhibition of NFκB 
activity also may be exerted through another cannabinoid receptor subtype, transfected 
BV-2 cells were treated with O-2095 as described previously.  O-2095 did not elicit an 
inhibitory response on NFκB transcriptional activity, and the level of transcriptional 
activity in O-2095-treated cells was comparable to levels observed with the LPS control 
treatment group (Figures 29).  Interestingly, cells treated with 10-6M concentration of O-
2095 without LPS stimulation demonstrated elevated levels of transcriptional activity, 
suggesting that O-2095 may participate in signaling events that induce the activation of 
NFκB.   
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Figure 29. The Non-CB1/Non-CB2 Selective Agonist O-2095 Does Not 
Inhibit the Transcriptional Activity of NFκB. NFκB reporter activity 
assays were performed on LPS-stimulated BV-2 cells pre-treated O-
2095 (3 h) at the indicated intervals. After LPS treatment, cells were 
collected, luciferase was extracted from lysed cells and measured.  
Background luciferase levels were substracted from each sample and 
normalized to β-galalctosidase levels.  Percent activity of all treatment 
groups was determined. O-2095 treated BV-2 overall exhibit the same 
level of transcriptional activity as LPS alone treated BV-2 cells. The 
results are presented as the mean ± SD, n=3. *p<0.01, for vehicle 
treated cells compared with LPS/vehicle treated cells. Ψp<0.01 and 
#p<0.05, for drug alone treated cells compared with vehicle treated and 
LPS/vehicle treated cells, respectively. 
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LPS-Induced Phosphorylation and Degradation of IκBα are Time-Specific.   
In addition to determining the specificity in which ∆9-THC and CP55940 down-
regulate NFκB activity, we also set out to determine the sites of action in which ∆9-THC 
and CP55940 inhibit NFκB function.  We proposed to determine whether cannabinoids 
inhibiting the binding and activity of NFκB through modulation of its conformation, or 
are affecting cellular events in the cytoplasm such as protein synthesis, phosphorylation, 
degradation and transport.  NFκB activation is rigorously controlled both extracellularly 
and intracellularly, and the rate-limiting step of NFκB activation is the phosphorylation 
and subsequent degradation of the inhibitor protein IκBα.  Prior to cell activation, IκBα 
sequesters NFκB in the cytoplasm by masking its nuclear localization signal, and upon 
cell activation, IκBα is phosphorylated at serine residues 32 (Ser32) and 36 (Ser36).  
Phosphorylated IκBα is then polyubiquitinated, and the ubiquitination of this protein 
marks it for degradation by the 26S proteasome.  The degradation of IκBα allows NFκB 
to translocate into the nucleus, bind to its cognate promoter binding sites and induce gene 
expression.  Since these early signaling events that result in the activation of NFκB take 
place rapidly, we first determined the time kinetics of IκBα phosphorylation.  For these 
experiments BV-2 cells were treated with vehicle or 100 ng/ml LPS for 5, 7.5, 10, 15, 
and 30 min.  Cytoplasmic and nuclear protein were extracted for analysis, and the 
cytoplasmic fractions were assessed for the phosphorylation and degradation of IκBα 
using antibodies specific for IκBα phosphorylated at Ser32/Ser36 and endogenous IκBα, 
respectively.  Phosphorylation of IκBα was observed as early as 5 min. post LPS 
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stimulation and was barely detectable by the 15 min. time point (Figure 30, top panel).  
There was no major induction of IκBα phosphorylation in the vehicle treated samples at 
the 5 min. and 30 min. time intervals.  To confirm equal protein loading, the blots were 
stripped and reprobed with beta-actin antibody (Figure 30, bottom panel).  Cytoplasmic 
protein fractions from the LPS-stimulated BV-2 cells also were analyzed by Western 
immunoblot analysis for LPS-induced degradation of IκBα.  Degradation of IκBα was 
observed 15 min. post LPS stimulation (Figure 31, top panel), which is complementary to 
the results obtained from Western immunoblot analysis of phosphorylated IκBα (Figure 
30).  Again, the blots were stripped and reprobed with a beta-actin antibody to assess for 
equal protein loading (Figure 31, bottom panel). 
 
∆9-THC and CP55940 do not Inhibit LPS-Induced Phosphorylation of IκBα. 
After determining the time kinetics of IκBα phosphorylation and degradation, we 
employed Western immuoblot analysis to determine if ∆9-THC and CP55940 modulate 
the phosphorylation and/or degradation of IκBα.  BV-2 cells were pre-treated with ∆9-
THC or CP55940 and then stimulated with 100 ng/ml LPS for 5 min.  As described 
previously, cytoplasmic protein was resolved by SDS-Page electrophoresis, electroblotted 
and probed with IκBα antibodies.  Results from these analyses demonstrated that 
phosphorylation of IκBα was not detected in unstimulated cells, as seen with vehicle and 
cannabinoid alone treated cells (Figures 32A and 32B).  Phosphorylation of IκBα 
occurred upon LPS stimulation and the same overall level of phosphorylation was 
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observed in cells pre-treated with ∆9-THC (Figure 32A, top panel) or CP55940 (Figure 
32B, top panel).  These results suggest that the inhibitory effects of ∆9-THC and 
CP55940 on NFκB function are independent of IκBα phosphorylation.  
 
∆9-THC and CP55940 Partially Inhibit the Degradation of IκBα Upon LPS 
Stimulation. 
 We also performed Western blot analysis on the endogenous IκBα protein to 
assess degradation of this protein and the possible cannabinoid effects on this cellular 
process.  IκBα is ultimately degraded by the 26S proteasome upon cell stimulation, and 
we demonstrated previously that this process occurs within 15 min. after LPS-induced 
cell activation.   BV-2 cells were pre-treated (3 h) with ∆9-THC or CP55940, followed by 
stimulation with 100 ng/ml LPS (15 min.).  Western immunoblot analyses were 
performed on cytoplasmic protein fractions using the anti-IκBα antibody described 
previously, and we observed IκBα degradation in LPS-stimulated BV-2 cells (Figures 
33A and 33B).  However, ∆9-THC (Figure 33A) and CP55940 (Figure 33B) treatment 
prior to LPS stimulation resulted in a decrease in the degradation of IκBα.  Cells that 
were treated with cannabinoids without LPS stimulation exhibited the same amount of 
IκBα in the cytoplasm as the untreated cells.  These results demonstrate that while ∆9-
THC and CP55940 do not affect the phosphorylation of IκBα, these compounds are able 
to diminish the LPS-induced, proteolytic degradation of this protein.  The ability of ∆9-
THC and CP55940 to inhibit degradation of IκBα suggests that these compounds may 
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affect actual proteolytic activity of the 26S proteosome or affect a regulatory event that 
happens after phosporylation, but prior to degradation, such as ubiquitination.   
 
∆9-THC does not Affect Synthesis and Phosphorylation of the p65 Subunit 
We investigated overall levels of p65 in both the cytoplasm and nucleus through 
Western immunoblot analyses.  BV-2 cells were pre-treated with ∆9-THC (3 h) and 
stimulated with 100 ng/ml LPS for 30 min.  Cytoplasmic and nuclear proteins were 
extracted and resolved by SDS-Page electrophoresis.  Western immunoblot analysis was 
performed using an anti-p65 antibody for detection in both the cytoplasm and nucleus.  
The levels of cytoplasmic p65 were comparable in all samples, demonstrating that 
synthesis of this protein is not affected by ∆9-THC (Figure 34A, top panel).  In nuclear 
samples, we observed a LPS-induced increase of p65 in the stimulated cells when 
compared to vehicle treated or cells treated only with cannabinoids, demonstrating 
apparent adequate transport of p65 into the nucleus upon cell activation.  The levels of 
nuclear p65 in cells treated with ∆9-THC were also comparable to those for the LPS 
treated samples (Figure 34B, top panel), suggesting that these exogenous cannabinoids 
do not affect the transport of p65 into the nucleus.  The blots were stripped and reprobed 
with beta-actin (Figure 34A, bottom panel) and proliferating cell nuclear antigen (PCNA)  
(Figure 34B  bottom panel) antibodies to assess for equal cytoplasmic and nuclear 
protein, respectively.   
Complete NFκB activation necessitates phosphorylation of the p65 subunit, which 
is carried out by several stimulant-specific serine kinases.  Serine residue 536 is located 
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in the transactivation domain of p65 and is phosphorylated by the IκB kinase (IKK) 
(Sakurai et al., 1999; Sakurai et al., 2003; Sizemore et al., 2002; Yang et al., 2003).  We 
assessed the time kinetics of LPS-induced p65 phosphorylation at Ser536, and the effects 
that cannabinoids may exert on its phosphorylation and transport into the nucleus.  
Cytoplasmic protein was assessed for the time kinetics of p65 phosphorylation using 
antibodies specific for p65 phosphorylated at Ser536, which is located in the 
transactivation domain of p65 and specifically phosphorylated by IKK.  BV-2 cells were 
treated with vehicle or 100 ng/ml LPS for 2.5, 5, 7.5, 10, 15 and 30min.  Cytoplasmic 
protein fractions were resolved by SDS-Page electrophoresis and electroblotted onto 
nitrocellulose membranes.  The LPS-induced phosphorylation of p65 at Ser536 was 
detected as early as 5 min. post LPS-stimulation, and was still detectable 30 min. post cell 
activation, although the level of phosphorylation has diminished some as compared to the 
earlier time points (Figure 35, top panel).  Basal levels of phosphorylation at this serine 
residue were detected in the vehicle treated cells, and cells stimulated with LPS for 2.5 
min.  Equal protein loading was assessed by probing the membranes with a beta-actin 
antibody (Figure 35, bottom panel).  We examined the effects that ∆9-THC may have on 
the cytoplasmic and nuclear levels of phospho (Ser536)-p65 using Western blot analysis.  
As described previously, BV-2 cells were pre-treated with ∆9-THC (3 h) followed by 
stimulation with 100 ng/ml LPS (15 min.).  Cytoplasmic and nuclear proteins were 
fractionated by SDS-Page electrophoresis, electroblotted onto nitrocellulose membranes 
and probed with the phospho-p65 antibody described previously.  In the cytoplasm, 
comparable levels of this phospho-protein were observed in all treatment groups (Figure 
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36A, top panel).  These results suggest that ∆9-THC does not modulate the 
phosphorylation of p65.  In the nucleus, we observed a LPS-induced increase of phospho-
p65 in LPS-stimulated cells as compared to the vehicle and ∆9-THC-treated cells (Figure 
36B, top panel).  Furthermore, levels of phospho-p65 in ∆9-THC-treated cells were 
similar to levels of phospho-p65 in LPS-stimulated cells, suggesting that ∆9-THC does 
not affect the transport of phosphorylated p65 into the nucleus.  The blots were stripped 
and reprobed with beta-actin (Figures 36A bottom panel) and proliferating cell nuclear 
antigen (PCNA)  (Figures 36B  bottom panel) antibodies to assess for equal cytoplasmic 
and nuclear protein, respectively.   
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Figure 30.  Rapid LPS-Induced Phosphorylation of IκBα in BV-2 Cells. BV-2 
cells were stimulated with vehicle (0.01% ethanol) or 100 ng/mL LPS for the 
indicated time intervals.  Cytoplasmic and nuclear protein was extracted 
from the cells, and the cytoplasmic fractions were resolved by SDS-PAGE. 
The resolved proteins were electroblotted onto to a nitrocellulose membrane 
and Western immunoblot analysis was performed using a phospho-IκBα 
antibody that detects IκBα when phosphorylated at serine residues 32 and 
36.  The results from this analysis demonstrate that IκBα is phosphorylated 
as early as 5 min. post LPS-induced cell activation.  The membrane was 
stripped and reprobed with a beta-actin antibody to assess for equal protein 
loading.   
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Figure 31.  Degradation of IκBα is Time Specific.  BV-2 cells were stimulated 
with vehicle (0.01% ethanol) or 100 ng/mL LPS for the indicated time 
intervals.  Cytoplasmic and nuclear protein was extracted from the cells, and 
the cytoplasmic fractions were resolved by SDS-PAGE.  The resolved 
proteins were electroblotted onto a nitrocellulose membrane and Western 
immunoblot analysis was performed using an IκBα antibody that detects the 
endogenous IκBα protein. The results from this analysis demonstrate that 
complete degradation of IκBα takes place 15 min. after LPS-induced cell 
activation.  The membrane was stripped and reprobed with a beta-actin 
antibody to assess for equal protein loading.   
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Figure 32. ∆9-THC and CP55940 do not Affect the LPS-Induced 
Phosphorylation of the NFκB inhibitor IκBα.  BV-2 cells were pre-treated (3 h) 
with ∆9-THC (A) or CP55940 (B) at the indicated intervals and stimulated (5 
min.) with 100 ng/ml LPS. Cytoplasmic protein extracts were subjected to 
Western blot analysis using an anti-phospho IκBα antibody which detects 
phosphorylated serine residues 32 and 36. Treatment with either ∆9-THC 
(panel A) or CP55940 (panel B) did not affect the phosphorylation of IκBα.  
Blots were stripped and reprobed for β-actin for assessment of equal protein 
loading. 
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Figure 33. ∆9-THC and CP55940 Partially Inhibit LPS-Induced Degradation of 
IκBα.  BV-2 cells were pre-treated (3 h) with ∆9-THC (A) or CP55940 (B) at 
the indicated intervals and stimulated (15 min.) with 100 ng/ml LPS. 
Cytoplasmic protein extracts were subjected to Western blot analysis using an 
anti-IκBα antibody which detects the endogenous IκBα protein. Degradation 
of IκBα was observed in LPS stimulated cells, however treatment with either 
∆9-THC (panel A) or CP55940 (panel B) resulted in decreased degradation of 
IκBα when compared to the LPS treated cells. Blots were stripped and 
reprobed for β-actin for assessment of equal protein loading. 
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Figure 34.  Protein Expression of Cytoplasmic and Nuclear p65.  BV-2 cells 
were pre-treated with vehicle (0.01% ethanol) or ∆9-THC (3 h) at the 
indicated intervals, followed by stimulation with 100 ng/mL LPS (30 min.).  
Cytoplasmic and nuclear protein were extracted from the cells, and both 
fractions were resolved by SDS-PAGE.  The resolved proteins were 
electroblotted onto a nitrocellulose membrane and Western immunoblot 
analysis was performed using specific a p65 antibody that detects the 
endogenous p65 protein.  (A), Cytoplasmic p65. Treatment with ∆9-THC did 
not affect the synthesis of p65 as comparable levels of protein expression 
were observed in all treatment groups. (B), Nuclear p65. Treatment with ∆9-
THC did not affect the translocation of p65 into the nucleus, nuclear protein 
expression of p65 in the cannabinoid-treated cells was similar if not greater 
than the LPS-stimulated cells.  The membranes were stripped and reprobed 
with a beta-actin and proliferating cell nuclear antigen (PCNA) antibodies to 
to assess for equal cytoplasmic and nuclear protein loading, respectively.   
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Figure 35.  LPS-Induced Phosphoryation of the NFκB p65 Subunit at Serine 
536.  BV-2 cells were stimulated with vehicle (0.01% ethanol) or 100 ng/mL 
LPS for the indicated time intervals.  Cytoplasmic and nuclear protein was 
extracted from the cells, and the cytoplasmic fractions were resolved by SDS-
PAGE.  The resolved proteins were electroblotted onto a nitrocellulose 
membrane and Western immunoblot analysis was performed using specific 
phospho-p65 antibody that detects p65 when phosphorylated at Ser536. 
Stimulus-induced phosphorylation at this residue begins as early as 5 min. 
post LPS stimulation and as late as 30 min. post stimulation.  The level of 
phosporylation is diminished by the time the 30 min. interval was reached. 
Basal levels of phosphorylation at this residue were observed in the vehicle 
treated cells and at 2.5 min. post LPS stimulation. The membranes were 
stripped and reprobed with a beta-actin antibody to assess for equal protein 
loading.   
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Figure 36.  ∆9-THC does not Affect LPS-Induced Phosphoryation of p65 at 
Serine 536 and its Nuclear Translocation.  BV-2 cells were pre-treated with 
vehicle (0.01% ethanol) or ∆9-THC (3 h) at the indicated intervals, followed 
by stimulation with 100 ng/mL LPS (15 min.).  Cytoplasmic and nuclear 
protein was extracted from the cells, and the cytoplasmic fractions were 
resolved by SDS-PAGE. The resolved proteins were electroblotted onto a 
nitrocellulose membrane and Western immunoblot analysis was performed 
using specific phospho-p65 antibody that detects p65 when phosphorylated at 
Ser536. (A), Phoshorylation of phospho-p65. Stimulus-induced 
phosphorylation at this residue was not affect by the treatment with ∆9-THC. 
(B), Nuclear translocation of phosphor-p65. The transport of this 
phosphorylated protein into the nucleus was not inhibited by ∆9-THC, as 
similar levels of protein expression were observed in all LPS-stimulated cells. 
The membranes were stripped and reprobed with a beta-actin and 
proliferating cell nuclear antigen (PCNA) antibodies to assess for equal 
cytoplasmic and nuclear protein loading. 
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Discussion 
 
 
 
 Microglia, as the resident macrophage of the central nervous system (CNS), have 
the critical role of remodeling and regenerating cells as well as providing the first line of 
defense against infection and injury (Cabral and Marciano-Cabral, 2005; Perry, 2004; 
Facchinetti et al., 2003; Aloisi, 2001; Blasi et al., 1990).  While the combined roles of 
microglia cells are to maintain an immunological homeostatic balance in the CNS, these 
cells also have been pathologically linked to the degeneration of the CNS.  Microglia 
become fully activated upon infection or injury and are able to elicit a whole host of pro-
inflammatory cytokines and other mediators as part of a typical immune response.  
However, activated microglia have been associated as a direct cause of, or a contributor 
to exacerbating a multitude of chronic neurodegenerative diseases that are pathologically 
hallmarked by an atypical production of pro-inflammatory factors.  These chronic 
diseases include Alzheimers disease (AD), Multiple Sclerosis (MS) and Human 
Immunodeficiency Virus encephalitis (HIVE).  The elicitation of pro-inflammatory 
factors from other cells within the CNS, and from infiltrated peripheral immune cells, 
also contributes to the pathology of neurodegenerative and neuroinflammatory diseases.  
 It has been well documented that cannabinoids can alter immune function of 
macrophages and macrophage-like cells such as microglia (Cabral andGriffin-Thomas, 
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2008; Cabral and Griffin-Thomas, 2009).  Thus, cannabinoid receptors have been 
explored for their therapeutic potential to serve as molecular targets for exogenous 
cannabinoids for the treatment of neuropathological disorders (Cabral and Griffin-
Thomas, 2008; Cabral and Griffin-Thomas, 2009).  In vitro and in vivo studies of MS and 
AD demonstrated that exogenous cannabinoids prevented activation of primary microglia 
and cognitive impairment in AD, and improved the motor function of mice suffering 
from a virus-induced demylinating disease that resembles MS (Arevalo-Martin et al., 
2003; Croxford and Miller, 2003; Ramirez et al., 2005a).  Immune modulation exerted by 
exogenous cannabinoids is believed to be consequential to the inhibition of adenylate 
cyclase activity, a primary effect of cannabinoid receptor signaling.  One of the important 
immune modulatory effects of exogenous cannabinoids such as ∆9-THC, the major 
psychoactive component of marijuana, is the modulation of gene expression of pro-
inflammatory cytokines.  ∆9-THC and the synthetic exogenous cannabinoids WIN55,212-
2 and CP55940 have been shown in microglia, astrocytes and macrophages to  inhibit 
LPS-induced pro-inflammatory cytokine (IL-1α, IL-1β, IL-6 and TNF-α) mRNA 
expression, ablate TNF-α release (Puffenbarger et al., 2000; Facchinetti et al., 2003) and 
inhibit production of nitric oxide (NO) through modulating the expression of inducible 
nitric oxide synthase (iNOS) (Coffey et al., 1996; Jeon et al., 1996; Molina-Holgado et 
al., 2002; Ross et al., 2000; Waksman et al., 1999).  The specific mechanisms in which 
exogenous cannabinoids reduce or inhibit the inducible expression of pro-inflammatory 
cytokine genes, particularly in microglial cells, have yet to be fully defined. The goal of 
the present study was to define the mechanisms of cannabinoid-mediated down-
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regulation of the inducible expression of pro-inflammatory cytokine genes in microglial 
cells. Previous studies have shown that overall mRNA degradation is not the causative 
factor for cannabinoid-mediated reduction in mRNA expression (Fischer-Stenger et al., 
1993; Puffenbarger et al., 2000). Therefore, we proposed that the modulation of pro-
inflammatory gene expression takes place at the transcriptional level.   
∆9-THC has been shown to modulate the activity of transcription factors to bind 
to specific cognate consensus binding sites in the promoter regions of specific genes 
(Kaminski, 1996).  This modulation of transcription factor activity was attributed to a 
down-stream effect of cannabinoid-mediated adenylate cyclase inactivity (Kaminski, 
1996).  One important transcription factor that binds to specific sites in the promoter 
region of pro-inflammatory cytokine genes is NFκB, a major role player in the 
inflammatory immune response.  NFκB can be activated by various stimuli, including 
bacterial LPS.  Initially, we entertained the use of mouse EOC-20 microglial cells as 
targets for assessing effects of cannabinoids on NFκB binding in response to stimulation 
with LPS.  Treatment of EOC-20 cells with TNF-α or IFN-γ resulted in an increase in 
p65 levels in the nucleus which is indicative of NFκB activation.  However, NFκB 
binding in EOC-20 cells stimulated with LPS was comparable to NFκB binding exhibited 
by unstimulated cells.  Ultimately, these cells were shown to lack expression of CD14, 
the co-receptor to TLR-4, and the lack of a complete TLR-4/CD14 complex prevents 
EOC-20 cells from signaling specifically through TLR-4 upon exposure to LPS.  
Therefore, subsequent experiments were performed using mouse BV-2 microglial-like 
cells.  BV-2 cells are phenotypically and functionally similar to primary microglia which 
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includes their ability to phagocytize, secrete cytokines and chemokines, and express a 
host of cell surface receptors.  Furthermore, our studies have demonstrated that these 
cells express CB2 at the mRNA and protein levels.  
Using the BV-2 cells, we first demonstrated LPS-induced binding of NFκB in 
vitro in both neonatal rat primary microglial cells and the BV-2 microglial cell line.  
Upon LPS stimulation, NFκB binding to a synthetic DNA probe that contains its cognate 
consensus sequence was observed as early as 15 min. post stimulation and more robustly 
at 30 min. post stimulation, which was the time point used in all subsequent binding 
studies.  We then analyzed the effects of the partial cannabinoid receptor agonist ∆9-THC 
on LPS-induced NFκB binding to nuclear promoter elements, which is critical for the 
induction of gene transcription.  It was observed that ∆9-THC inhibited NFκB binding in 
a biphasic, concentration-related manner.  BV-2 cells treated with a 10-5M concentration 
of ∆9-THC displayed decreased levels of NFκB binding as compared to cells stimulated 
with LPS alone.  We accounted this phenomenon to the toxic effects of such a high 
concentration of the highly lipophilic ∆9-THC compound, which has been shown to 
perturb lipid-bilayers of cellular membranes (Makriyanni et al., 1990; Martin 1986), and 
cause apoptosis in microglial-like BV-2 cells (data not shown).  The 10-6M concentration 
did not exert an effect on NFκB binding when compared to BV-2 cells treated with  LPS 
alone, suggesting that the inhibitory effect observed at the 10-5M concentration was no 
longer established at the more diluted 10-6M concentration.  ∆9-THC exerted inhibitory 
effects at the 10-7M and 10-8M concentrations, with the greatest inhibition occurring at 
10-8M.    The level of NFκB binding at the 10-9M and 10-10M concentrations was 
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comparable to that of LPS-stimulated cells at the 10-6M concentration.  The response 
pattern that ∆9-THC exerted on NFκB binding is consistent with that from published 
studies that report biphasic effects exerted by cannabinioids (Little and Martin, 1991; 
Kujtan et al., 1993; Berdyshev et al., 1997).  Cannabinoids, at higher concentrations, can 
display a pattern of responsiveness that is the result of non-specific modes of action, such 
as perturbation of cellular membranes and/or cell apoptosis.  The inhibitory responses 
elicited as concentrations approach nanomolar levels are indicative of a more specific 
mode of action such as receptor-mediated.  Further indication of concentration-related, 
receptor- mediated effects exerted by lower concentrations of ∆9-THC is the observation 
that the inhibitory effects taper off as the concentrations are further diluted (10-9M and 
10-10M concentrations).  In agreement with previous studies, the results of these binding 
experiments demonstrate the dual mode of action of ∆9-THC on LPS-induced NFκB 
binding.   
A similar mode of action on NFκB binding was exhibited with the full 
cannabinoid receptor agonist CP55940.  As described with ∆9-THC, we observed 
attenuated levels of NFκB binding at the 10-5M, which dissipated at the 10-6M 
concentration.  However, CP55940 exerted a concentration-related inhibition of NFκB 
binding over an extended range (10-7M  10-9M), with maximum inhibition occurring at 
the 10-9M concentration.  The level of binding at the 10-10M concentration was 
comparable to that of the LPS treatment group.  CP55940, as a full agonist, has greater 
efficacy than ∆9-THC which is a partial agonist, so the extended inhibitory effect on 
NFκB binding exerted by CP55940 was not surprising.  The results from the ∆9-THC and 
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CP55940 studies demonstrate cannabinoid-mediated effects on NFκB binding, but do not 
indicate whether these effects are functionally linked to the transcriptional activity of 
NFκB. 
Exogenous cannabinoids and the endogenous cannabinoid anandamide have been 
shown to inhibit the transcriptional activity of NFκB in cell types other than microglia 
(Sancho et al., 2003; Curran et al., 2005).  Our study represents the first analysis of the 
effects of cannabinoids on microglial-like cells.  In initial studies, BV-2 microglial-like 
cells upon LPS-stimulation for 3h, 8h and overnight exhibited a significant increased 
level of NFκB transcriptional activity as compared to unstimulated cells.  A robust 
increase in transcriptional activity at the 3h time interval was observed and therefore, was 
used in all subsequent reporter activity studies.  BV-2 cells exposed to ∆9-THC prior to 
stimulation with LPS exhibited attenuated levels of LPS-induced transcriptional activity 
in a concentration-related fashion (10-7M - 10-9M).  Maximum inhibition occurred at the 
10-8M concentration, consistent with results obtained in the NFκB binding assays.  The 
level of transcriptional activity at the 10-6M and 10-10M concentrations were comparable 
to those of the LPS-treated cells; again, this pattern of responsiveness demonstrated a 
biphasic mode of action of ∆9-THC.  Similarly, CP55940 inhibited the transcriptional 
activity of NFκB over the same concentration range (10-7M - 10-9M) but the extent of the 
inhibition was greater with the more efficacious CP55940 compound.  The concentration-
related effects that both ∆9-THC and CP55940 are exerting on the functional activity of 
NFκB suggest a specific mode of action that is receptor-mediated.  In order to establish a 
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linkage to either of the two cannabinoid receptors, we performed a series of experiments 
to determine the specificity in which these inhibitory effects are occurring.   
Real-Time RT-PCR analysis revealed that mRNA for CB1 is not detected in 
unstimulated BV-2 cells and cells activated with IFN-γ or LPS.  Southern blot analysis 
confirmed the absence of CB1 mRNA.  However, Real-Time RT-PCR analysis 
demonstrated that BV-2 cells exhibit a base-line level of expression of the CB2, as 
detection of CB2 mRNA was observed in unstimulated cells.  BV-2 cells stimulated with 
either IFN-γ or LPS exhibited variable expression of CB2 mRNA, consistent with reports 
that microglial differentially express the CB2 based on their different activation states 
(Carlisle et al., 2002).  Southern blot analysis confirmed the presence of CB2 mRNA in 
both unstimulated and stimulated BV-2 cells.  To further elucidate the specificity in 
which ∆9-THC and CP55940 are inhibiting NFκB function, we again performed NFκB 
reporter activity assays using CB1 and CB2 selective agonists and antagonists.  The CB1 
selective agonist ACEA did not inhibit the transcriptional activity of NFκB, which was 
not surprising since BV-2 cells were shown to not express CB1 at the mRNA and protein 
levels.  In addition, the inhibitory effect of 10-7M CP55940 on transcriptional activity was 
not reversed by the CB1-selective antagonist SR141716A, thus further confirming the 
lack of involvement of the CB1.  These finding are consistent with published reports that 
indicate that the CB1 is not linked to the modulation of most immune responses, (Cabral 
and Griffin-Thomas, 2009).  However, the CB2 has been functionally linked to the 
modulation of inflammatory immune responses in both the periphery and the CNS 
(Cabral and Griffin-Thomas, 2008; Cabral and Griffin-Thomas, 2009).   
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 Reporter activity assays performed with the CB2 selective ligand O-2137 
indicated that this compound exerted an inhibitory effect on transcriptional activity.  
However, while the inhibitory effect of O-2137 was significant from the 10-7M - 10-10M 
range, the percentage of inhibition when compared to LPS-stimulated cells was not 
robust.  To further explore whether the CB2 played a role in modulating the function of 
NFκB, we employed the CB2-selective antagonist SR144528 in concert with CP55940 
for a subsequent set of reporter activity studies.  The CB2-selective antagonist was able to 
block CP55940-mediated inhibition of NFκB transcription.  These findings are contrary 
to other published reports that indicate that exogenous and endogenous cannabinoids 
inhibit inducible NFκB transcriptional activity independent of either cannabinoid 
receptor.  Curran and colleagues reported that the exogenous cannabinoid WIN55212,2 
inhibits IL-1 signaling in astrocytes, which prevents induction of cell adhesion molecules 
and the chemokine IL-8 (Curran et al., 2005).  They attributed WIN55212,2-mediated 
inhibition of IL-1 signaling to WIN55212,2 suppressing NFκB transcriptional activity.  
However, they reported that neither CB1 or CB2 was involved in the process since the 
astrocyte cell line used in the studies does not express mRNA for either receptor and CB1 
and CB2 -selective antagonists did not block the inhibitory effects of WIN55212,2 on the 
induction of adhesion molecules.  Sancho and colleagues reported that the endogenous 
cannabinoid anandamide inhibits NFκB activity in a cannabinoid-receptor independent 
manner (Sancho et al., 2003).  The Jurkat 5.1 clone was used as their cell model, a clone 
that was shown to express CB2 but not CB1 mRNA.  NFκB reporter activity assays 
demonstrated that anandamide exerted a concentration-related inhibition on 
 106
transcriptional activity, although it should be noted that relatively high levels of 
anandamide range from 5µM to 25µM (5x10-6M  2.5x10-5M) were used to obtain such 
an effect.  This inhibition of transcriptional activity was not blocked by the CB1 and CB2 
antagonists SR141716A and SR144528, respectively.  There are several explanations that 
may account for our disparate results.  First, the findings reported in this dissertation 
versus those of Curran and colleagues (Curran et al., 2005), and Sancho and colleagues 
(Sancho et al., 2003) may indicate that the specificity of action for exogenous 
cannabinoids may be cell-specific.  Second, it should also be considered that inhibitory 
effects observed around the non-pharmacological range such as 10µM (10-5M) may be 
due to non-receptor specific action such as membrane perturbation and toxicity that may 
cause apoptosis.  In this context, cannabinoid-mediated effects observed in our studies 
were in the range of 0.1µM to 0.001µM (10-7M  10-9M), and the CB2 antagonist 
SR144528 was able to block the effects of 0.1µM CP55940.  Our findings, however, are 
consistent with other reports that show that the CB2 more than the CB1 is involved in 
ablating the production of pro-inflammatory mediators in microglia cells.  Eljaschewitsch 
and colleagues reported that anandamide attenuated the production of nitric oxide (NO) 
via reducing iNOS gene expression (Eljaschewitsch et al., 2006).  While CB1 antagonism 
provided a minor reversal of NO inhibition, antagonizing the CB2 completely abolished 
the anti-inflammatory effects of anandamide.  Also consistent with our findings are 
reports that demonstrate CB2-mediated attenuation of TNF-α, IL-1, IL-6 and IL-8 
production in macrophages (Klegeris et al., 2003; Berdyshev et al., 1997; Gallily et al., 
2000).  The elicitation of TNF-α and IL-1 has been shown to induce NFκB activation, 
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thus participating in an autoregulatory feedback loop that regulates and deregulates 
NFκB activity (Blackwell and Christman, 1997; Lawrence et al., 2001; Ye and Johnson, 
2001).   
In addition to defining the specificity of action in which the exogenous 
cannabinoids ∆9-THC and CP55940 inhibit NFκB activity, our studies also involved 
identifying the site of action of these compounds.  It has been reported that both 
cannabinoid receptors play a role in activating or regulating signaling pathways involving 
adenylate cyclase/cAMP, mitogen-activated protein kinase (MAPK), cAMP-dependent 
protein kinase (PKA) and a host of transcription factors and their specific regulators 
(Howlett and Mukhopadhyay, 2000; Demuth and Molleman, 2006).   CB1 and CB2 are 
negatively coalesced to adenylate cyclase, which results in a decreased production of 
cAMP.  Upon cannabinoid binding to either cannabinoid receptor, the activated, 
heterotrimeric G-protein uncouples into alpha (α) and beta/gamma (βγ) subunits, and the 
βγ subunit participates in signaling cascades distinct from those of the α subunit, such as 
the MAPK cascade (Howlett and Mukhopadhyay, 2000).  The inhibitory α subunit is 
responsible for the stifling of adenylate cyclase activity and production of cAMP.  This 
lack of cAMP production impedes downstream cAMP-mediated signaling events such as 
PKA catalytic activity, and transcription factor activation.  These specific sites may 
represent target points for cannabinoid-mediated action that could ultimately result in the 
down-regulation of immune function, particularly pro-inflammatory cytokine expression 
in microglia cells.     
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The transcription factor NFκB plays a major role in inducing the inflammatory 
response, so stringent control of its activation is required for proper immune function 
(Blackwell and Christman, 1997).  Prior to translocating into the nucleus, binding to 
specific promoter elements, and inducing transcription of NFκB-regulated genes, NFκB 
is retained in the cytoplasm by its inhibitor protein IκBα.  Upon cell activation, IκBα is 
rapidly phosphorylated, ubiquitinated and degraded by the 26S proteosome, thereby 
allowing for the nuclear translocation of NFκB.  In order to address whether 
cannabinoids altered any of these events, we first performed a set of experiments to 
determine if the specific site in which cannabinoids act to inhibit NFκB function involved 
IκBα.  Since the phoshorylation of IκBα at serine residues 32 and 36 initiates its 
ubiquitination and degradation, we assessed the effects of ∆9-THC and CP55940 on this 
regulatory event.  Both cannabinoid compounds were shown not to inhibit LPS-induced 
phosphorylation of IκBα.  In concert with the previous set of experiments, we also 
determined if ∆9-THC and CP55940 inhibited the degradation of IκBα.  We observed 
that both compounds inhibited full degradation of IκBα upon LPS-induced cell 
activation.  These findings are consistent with reports from Sancho and colleagues 
(Sancho et al., 2003) that indicated that anandamide inhibited the transcriptional activity 
of NFκB in part by inhibiting TNF-α-induced degradation of IκBα.  However, Sancho 
and colleagues also reported that the lack of IκBα degradation was due to anandamide 
inhibiting the catalytic activity of IκB kinase (IKK), the kinase responsible for the 
phosphorylation of IκBα (Sancho et al., 2003).  These results should be considered in the 
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context that the anandamide-mediated effects on NFκB activity and regulation observed 
with Sanchos group were indicated to be independent of cannabinoid receptor signaling.  
Since our studies demonstrated a linkage of the CB2 in the inhibition of NFκB activity, 
we have to consider that the lack of IκBα degradation is a consequence of cannabinoid-
mediated adenylate cyclase inhibition which modulates further downstream signaling 
events, thus resulting in a defect in ubiquitination and/or proteolytic degradation.  As 
described previously, adenylate cyclase inhibition results in a lack of cAMP production 
that stifles the catalytic activity of PKA.  The ubiquition-proteasome pathway has been 
shown to be dependent on and regulated by PKA (Hoang et al., 2004; Zhang et al., 2007).  
Specific serine phosphorylation of one the 26S proteasome ATPases by PKA stimulates 
the activity of the proteasome.  Our findings also are consistent with a study that 
demonstrated that ∆9-THC, with the involvement of the CB2 receptor, may interfere with 
the enzyme activity of some proteases in macrophages and prevent proper antigen 
processing for T cell stimulation (McCoy et al., 1995; McCoy et al., 1999).  However, 
further studies are required in order to establish a link between ∆9-THC and CP55940-
mediated inhibition of IκBα degradation and modulation of the ubiquitin/ proteasome 
pathway.  
Another regulatory component for complete NFκB activation requires 
phosphorylation of the p65 subunit at serine residues 276, 529 and 536.  Serine residue 
536, phosphorylated by IKK upon TNF-α or LPS stimulation, is located in the 
transactivation domain (TAD) of p65 and is important for the activation and 
transcriptional activity of NFκB.  Using an antibody specific for the detection of p65 
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Figure 37. Cannabinoid-Mediated Inhibition of LPS-Induced NFκB Activity in BV-
2 Cells.  The exogenous cannabinoids ∆9-THC and CP55940 inhibit NFκB activity, 
in part, by signaling through the CB2.  Upon treatment of BV-2 cells with either ∆9-
THC or CP55940, activation of the CB2 commences with the dissociation of the 
inhibitory G-protein into β/γ and α subunits.  The α subunit binds to adenylate 
cyclase and prevents the production of cAMP, and the kinase activity of PKA.  Once 
cannabinoid-treated BV-2 cells are stimulated with LPS, a stimulatory signaling 
pathway is initiated through TLR-4.  Concurrently with TLR-4 signaling, the β/γ 
subunit can induce activation of MAPK signaling, which can also activate NFκB.  
From our studies, it was demonstrated that ∆9-THC and CP55940 did not inhibit 
phosphorylation of the inhibitor protein IκBα but inhibited its degradation.  
Therefore, we propose that CB2 signaling superimposes an inhibitory effect on TLR-
4 and/or MAPK signaling at the ubiquitin/proteasome degradative pathway, thus 
preventing IκBα degradation and ultimately NFκB activity. 
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when phosphorylated at serine 536, we observed that LPS-induced phosphorylation of 
this residue is not affected by ∆9-THC.  Furthermore, ∆9-THC did not affect the 
translocation of phospho-p65, as comparable levels of this phospho-protein were detected 
in the nuclear protein extracted from LPS-stimulated and ∆9-THC-treated BV-2 cells.  ∆9-
THC also did not affect overall synthesis or transport of the endogenous p65 protein as 
seen in both cytoplasmic and nuclear protein fractions.  Consistent with our findings, 
Curran and colleagues reported that, while WIN55212,2 inhibited the transcriptional 
activity of NFκB, it did not affect translocation of activated p65 into the nucleus (Curran 
et al., 2005).   
The inhibition of NFκB binding and transcriptional activity exerted by ∆9-THC 
and CP55940 appears to be a consequence of these compounds inhibiting the degradation 
of IκBα which would constitute retainment of the IκBα/NFκB complex in the cytoplasm, 
and result in a lack of unbound, activated NFκB translocating to the nucleus.  However, 
results from Western immunoblot analyses demonstrated that phosphorylation and 
nuclear translocation of the p65 subunit was not modulated by cannabinoids.  Therefore, 
we postulate that multiple signal transduction cascades are involved in cannabinoid-
mediated modulation of LPS-induced NFκB binding and activity.  Eljaschewitsch noted 
that inhibition of signal transduction in microglial cells requires parallel activation of 
multiple signaling cascades, including signaling of pattern recognition receptors, such as 
the Toll-like receptor 4 (TLR-4), which recognizes and binds to bacterial LPS 
(Eljaschewitsch et al., 2006).  In our in vitro cell model, LPS-induced signaling followed 
cannabinoid receptor activation in which distinct signaling pathways are activated by the 
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α and βγ subunits of the cannabinoid-receptor coupled Gi protein.  As described 
previously, signal transduction of the α subunit, which inhibits adenylate cyclase activity 
and cAMP production, modulate further downstream cAMP and/or PKA-dependent 
signaling events that ultimately affects the ubiquitin/proteasome pathway.  Concurrent 
with Gi-α inhibitory signaling, Gi-βγ and LPS-mediated stimulatory signaling lead to the 
activation of NFκB through the MAPK signaling and TLR-4 signaling networks, 
respectively.  These signaling cascades allow phosphorylation and activation of specific 
kinases (i.e., IKK, MAPK) that result in the normal phosphorylation of the p65 subunit 
and IκBα but not its degradation, as observed in cannabinoid-treated BV-2 cells.  It is 
likely that Gi-α signaling converges onto the stimulatory signaling that results in NFκB 
activation at the ubiquitin/proteasome step and superimposes an inhibitory effect on one 
or both of these processes (Figure 37).  While the convergence of these signaling 
cascades may explain the cannabinoid-mediated modulation of IκBα degradation 
observed in our studies, its does not fully explain how activated NFκB, in terms of the 
p65 subunit, is still able to translocate into the nucleus, and possibly induce gene 
expression.  One explanation is that there is still some nominal level of NFκB occurring, 
which is demonstrated by the fact that ∆9-THC or CP55940 did not completely inhibit 
NFκB activity.  Furthermore, it was demonstrated that the CB2 antagonist SR144528 did 
not fully reconstitute the transcriptional activity of NFκB when inhibited by CP55940. It 
should be noted that one of the genes that can be induced by this nominal level of NFκB 
activity is its inhibitor IκBα.  Indeed, reports have demonstrated that newly synthesized 
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IκBα can translocate into the nucleus, bind to NFκB and prevent its transcriptional 
activity (Arenzana-Seisdedos et al., 1997; Chiao et al., 1994; Sachdev et al., 2000; 
Rodriguez et al., 1999; Huang et al., 2000).  The consequent binding of IκBα to NFκB 
interferes with the conformation of NFκB in that proper binding to its DNA promoter 
cannot be established.  This phenomena may detail an additional mechanism of action 
located specifically in the nucleus that would further inhibitory NFκB binding and 
transcriptional activity (Figure 38).   
Another explanation as to how cannabinoids may affect the activity of NFκB once 
it has localized to the nucleus is the involvement of glucocorticoid receptors.  
Glucocorticoids are steroid hormones that bind to, and activate, glucocorticoid receptors 
(GCR).  GCRs have been shown to exhibit anti-inflammatory modes of action upon 
activation by translocating into the nucleus and repressing gene transcription of pro-
inflammatory cytokines and chemokines (Adcock, 2001a; Adcock and Caramori, 2001b).  
It has been reported that GCRs have direct protein-protein interactions with transcription 
factors involved in inducing the inflammatory response such as NFκB, and alter their 
ability to bind to DNA promoter elements and induce gene expression (Karin M, 1998; 
Kagoshima et al., 2003).  Endogenous cannabinoids, as well as the exogenous 
cannabinoids ∆9-THC and cannabidiol, have been shown to bind to GCRs due to their 
structural similarity to steroid hormones (Eldridge et al., 1991).  ∆9-THC has been shown 
to displace binding of steroid hormones to GCRs, thus serving as a potential competitor 
to these compounds.  The effects elicited from ∆9-THC-GCR interaction have been 
reported to be similar to those effects observed in glucocorticoid-GCR interactions 
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(Eldridge and Landfield, 1990; Eldridge, 1991).  Thus, ∆9-THC in exhibiting agonist-like 
behavior for GCRs could activate these receptors.  The activation of GCRs by ∆9-THC 
and CP55940 may describe another mode of action in which cannabinoids down-regulate 
the activity and function of NFκB (Figure 39).  The results of our studies demonstrate 
that more than one role player is involved in cannabinoid-mediated inhibition of NFκB 
activity.  However, further studies are required in order to establish whether these 
multiple signaling cascades are involved and are acting in concert with, or independently 
of, one another.   
In summary, we have demonstrated that the exogenous cannabinoids ∆9-THC and 
CP55940 inhibit the functional activity of the universal transcription factor NFκB.  Both 
∆9-THC and CP55940 were found to diminish the binding of NFκB to synthetic DNA 
probes containing its consensus sequence.  In addition, the ability of NFκB to transcribe a 
reporter gene (Luc) was attenuated by these compounds.  This inhibitory effect was 
linked functionally to the CB2, for the inhibitory effects of CP55940 on transcriptional 
activity was significantly blocked by the CB2-selective antagonist SR144528.  To define 
the site of action in which CB2 signaling results in NFκB malfunction, we examined the 
effects of ∆9-THC and CP55940 on the IκBα protein that strictly regulates its activation.  
Neither cannabinoid compound had an affect on the phosphorylation of this regulatory 
protein which constitutes an initial step in activating NFκB upon cell stimulation.  
However, ∆9-THC and CP55940 were found to inhibit the degradation of IκBα which 
entails the rate-limiting step in NFκB activation.  These results suggest that cannabinoids  
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Figure 38. Inhibition of NFκB Binding and Transcriptional Activity in BV-2 
Cells via Autoregulation.  Our results indicate that a nominal level of NFκB 
activity persists by way of TLR-4 or MAPK signaling (1).  This was 
demonstrated by the lack of inhibition that ∆9-THC exerted on the translocation 
of activated phospho-p65 into the nucleus (2), and by the fact that neither ∆9-
THC nor CP55940 fully inhibited NFκB transcriptional activity.  We postulate 
that there may be other mechanisms of action that also inhibit NFκB binding 
and transcriptional activity, despite the presence of some level of NFκB activity.  
We further speculate that this nominal level of NFκB activity results in gene 
expression of NFκB -regulated genes, such as the gene for its inhibitor IκBα 
(NFKBIA) (3). Expression of NFKBIA results in newly synthesized protein that 
has yet to bind to NFκB (4).  It has been shown that newly synthesized, unbound 
IκBα can translocate into the nucleus and bind to activated NFκB (5). The 
binding of IκBα  to NFκB prevents its binding and subsequent transcriptional 
activity (6), thus NFκB autoregulates itself by inducing gene expression of its 
inhibitor, IκBα. 
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Figure 39. Inhibition of NFκB Binding and Transcriptional Activity in BV-2 
Cells via Transrepression. Our results indicate that there still is a nominal level 
of NFκB activity occurring by way of TLR-4 or MAPK signaling.  This was 
demonstrated by the lack of inhibition that ∆9-THC exerted on the translocation 
of activated phospho-p65 into the nucleus, and by the fact that neither ∆9-THC 
nor CP55940 fully inhibited NFκB transcriptional activity. One explanation is 
that NFκB may autoregulate itself by inducing gene expression of its inhibitor 
IκBα, which can translocate into the nucleus, bind to NFκB, and prevent its 
binding and activity (Figure 38). We also postulate that NFκB activity may be 
repressed through interaction with glucorticoid receptors (GCR). Cannabinoids 
such as ∆9-THC can readily pass through cellular membranes and enter the 
cytosol (1).   Specifically, ∆9-THC has been shown to bind and activate GCRs (2), 
which reside in the cytosol.  The activated GCR, complexed with ∆9-THC, can 
translocate to the nucleus and bind to NFκB (3).  Binding of GCRs to NFκB 
prevents the proper binding and subsequent transcriptional activity of NFkB, 
thus repressing NFκB activity (4).
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degradation by the 26S proteasome, or have an affect on the proteolytic activity of the  
26S proteasome.  We also determined the effect of ∆9-THC and CP55940 on the p65 
subunit of NFκB, which plays a critical role in DNA binding and transcriptional activity.  
Overall synthesis and transport of p65 was not affected by ∆9-THC and CP55940.  In 
addition, neither ∆9-THC nor CP55940 had an effect on the phosphorylation of p65 at its 
serine 536 site and its translocation into the nucleus, both of which is required for 
complete transactivation of NFκB.   
Collectively, our results suggest that in addition to the exogenous cannabinoids 
∆9-THC and CP55940, through the CB2, mediating the modulation of NFκB function in 
microglial-like cells in part by inhibiting the proteolytic degradation of IκBα, there is 
also a mechanism of action in the nucleus by which these exogenous cannabinoid 
compounds prevent the proper binding and subsequent transcriptional activity of NFκB, 
the major inducer of the inflammatory immune response.  Importantly, these studies 
demonstrate the therapeutic potential of cannabinoids and the CB2 as a molecular target 
for ablating neuropathies and other neurodegenerative disorders that are pathologically 
hallmarked by a chronic elicitation of pro-inflammatory mediators in large part by 
activation of microglia cells that is mediated through NFκB.   
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